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        Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor suppressor disorder 
characterized by hamartomas, or benign growths, in various organ systems. Inactivating 
mutations in either the TSC1 or the TSC2 gene cause most cases of TSC. Recently, the use 
of ovarian specific conditional knock-out mouse models has demonstrated a crucial role of the 
TSC genes in ovarian function. Mice with complete deletion of Tsc1 or Tsc2 showed 
accelerated ovarian follicle activation and subsequent premature follicular depletion, consistent 
with the human condition premature ovarian failure (POF). POF is defined in women as the 
cessation of menses before the age of 40 and elevated levels of follicle stimulating hormone 
(FSH). The prevalence of POF is estimated to be 1%, affecting a substantial number of 
women in the general population. Nonetheless, the etiology of most cases of POF remains 
unknown. Based on the mouse model results, we hypothesized that the human TSC1 and 
TSC2 genes are likely to be crucial for ovarian development and function. Moreover, since 
women with TSC already have one inactivated TSC gene, we further hypothesized that they 
may show a higher prevalence of POF. To test this hypothesis, we surveyed 1000 women with 
TSC belonging to the Tuberous Sclerosis Alliance, a national support organization. 182 
questionnaires were analyzed for information on menstrual and reproductive function, as well 
as TSC. This self-reported data revealed 8 women (4.4%) with possible POF, as determined 
by menstrual history report and additional supportive data. This prevalence is much higher 
than 1% in the general population. Data from all women suggested other reproductive 
pathology associated with TSC such as a high rate of miscarriage (41.2%) and menstrual 
irregularity of any kind (31.2%). These results establish a previously unappreciated effect of 
TSC on women’s reproductive health. Moreover, these data suggest that perturbations in the 
cellular pathways regulated by the TSC genes may play an important role in reproductive 
function. 
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Background 
 
Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by 
the formation of hamartomas, or benign growths, in various organs of the body. TSC is 
estimated to affect 1/6000 – 1/10000 individuals. The disorder is caused by an inherited or de 
novo mutation in either the TSC1 or TSC2 gene.  Approximately 30% of cases are inherited 
from an affected parent, and 70% represent de novo germline mutations.  While TSC can 
affect any organ system, major manifestations often occur in the brain, skin and kidney. 
Approximately 50% of individuals will develop seizures and many have neuropsychiatric illness 
and/or behavioral problems. TSC is diagnosed clinically, but molecular testing of TSC1 and 
TSC2 is available for confirmation, accurate recurrence risks, and information for families.  
History  
The French neurologist Désiré-Magloire Bourneville is credited with naming tuberous 
sclerosis, or, as he stated in 1880, “tuberous sclerosis of the cerebral convulsions 
[Bourneville].” Bourneville described several findings in a deceased young woman with a 
history of some degree of mental retardation, facial angiofibromas, and epilepsy since infancy. 
Several sclerotic lesions in her brain were noted to be dense and “potato-like,” and Bourneville 
concluded they were the likely cause of her seizures. He also noted masses in both of her 
kidneys but believed they were independent of the brain pathology. The eponym Bourneville 
disease was used well into the 20th century. The term Tuberous Sclerosis Complex is 
attributed to Sylvan E. Moolten, who in 1942 proposed the name to reflect the heterogeneity of 
the disorder. He also established “hamartoma” as the term for the pathologic tumors [Moolten].  
The genetic etiology of TSC would not be uncovered until the early 1990s, but other 
important genetic concepts were realized as early as 1910. Kirpicznik documented the 
presence of TSC in three successive generations of one family [Kirpicznik]. Years later, 
Gunther and Primrose confirmed the hereditary nature of TSC, and commented that a high 
mutation rate must be present to account for the number of affected individuals with no family 
history [Gunther]. Lastly, the term “forme frusta” TSC (from the French word for fluster, or 
defaced) was used by Schuster to refer to those individuals who met some, but not all of the 
existing diagnostic criteria. This early recognition of variable expression foreshadowed a 
difficulty in the recognition and diagnosis of TSC that still exists today; fewer than 40% of 
affected individuals meet the classic “triad” of seizures, mental retardation, and facial 
angiofibromas [Kwaiatkowski; Curatolo, 2003].  
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Early studies of TSC involved patients in mental institutions, and indeed the presence of 
mental impairment was an initial part of TSC diagnostic classification [Chao]. However, a study 
of individuals with TSC performed in the late 1960s showed over one third of individuals were 
of average intelligence, and over 60% had some learning disabilities [Lagos]. This marked 
phenotypic variability, contributed to multiple revisions of diagnostic criteria [Gomez; Roach, 
1998; Roach, 2004]. The current diagnostic criteria for TSC are separated into major and 
minor criteria. Individuals with two or more minor features or with one major feature alone are 
considered “Possible TSC.” Those with one major feature and one minor feature are “Probable 
TSC.” Finally, the presence of two major features or of one major feature plus two minor 
features is deemed “Definite TSC.” These features are listed in the table below [Roach, 2004].  
Major Features Minor Features 
Facial angiofibromas or forehead plaque 
Multiple randomly distributed dental 
enamel pits 
Nontraumatic ungual or periungual fibromas Hamartomatous rectal polyps 
Three of more hypomelanotic macules Bone cysts 
Connective tissue nevus 
Cerebral white matter radial migration 
lines 
Multiple retinal nodular hamartomas Gingival fibromas 
Cortical tuber Nonrenal hamartoma 
Subependymal nodule Retinal achromic patch 
Subependymal giant cell astrocytoma 
 
Cardiac rhabdomyoma, single or multiple 
Lymphangioleiomyomatosis 
Renal angiomyolipoma 
 
Manifestations 
TSC has the potential to affect any organ system in the body. Descriptions of the most 
common findings are presented below.  
Dermatologic Lesions 
Virtually all individuals with TSC have skin lesions that are often clues for the 
diagnostician. Hypopigmented macules, the most common skin findings, are present in nearly 
all individuals. These lesions usually have a sharp border, are elliptical, and show improved 
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visibility under a Wood’s light, which is useful for examining individuals with fair skin 
[Fitzpatrick; Leung]. Importantly, in the absence of prenatal findings, hypopigmented macules 
are often the first signs of TSC, as they are present at birth. The next most common 
dermatological lesions are facial angiofibromas, present in approximately 47-90% of affected 
individuals. These typically do not appear until late childhood and early adolescence 
[Curatolo]. The appearance of angiofibromas is often psychologically disturbing to patients. 
Another skin finding, hypopigmented macule (previously “shagreen patch)” is present in 20% - 
80% of individuals. It is typically located in the lumbar region or the nape of the neck and often 
appears with satellite lesions. The skin is usually leathery, and can be dimpled like an orange 
peel [Webb]. 
Fibrous facial plaques are slow growing, raised, flesh-colored plaques seen in about 19% 
of individuals [Jozwiak].  Finally, ungual fibromas occur in 17- 87% of individuals with TSC. 
These are tumors of the fingernails and toenails and are found more commonly in the latter 
[Osborne]. The fleshy lesions can occur underneath and/or around the nails.  
Neurologic manifestations 
The neurologic manifestations of TSC often cause the classic features of intellectual 
impairment, epilepsy, and behavioral problems. These complications are the most common 
causes of morbidity and mortality, severely affecting individuals’ quality of life. About half of 
individuals with TSC have normal intellect. Between ten and fifteen percent do not have 
seizures [O’Callaghan; Sparagana & Roach].  
Intracranial lesions include cortical tubers (in 70% of individuals), subependymal nodules (in 
90% of individuals), and subependymal giant cell astrocytoma (in 6 -14% of individuals). 
Tubers are typically usually present at birth and can be numerous [Leung]. Subependymal 
nodules are lesions lining the lateral ventricular system of the cerebral hemispheres. The 
lesions are usually multiple and small, and rarely cause clinical problems [Leung; Roach, 
2004].  
Subependymal giant cell astrocytomas (SEGAs) are benign tumors located in the lateral 
ventricles near foramen of Monro. It is hypothesized that they develop from sub-ependymal 
nodules, and indeed, the histology of both lesions are indistinguishable. However, they can be 
visualized if they sustain significant growth. There is a risk for SEGAs to lead to an obstruction 
of CSF outflow and become symptomatic. Prior to improvements in imaging and guidelines for 
routine screening, patients often presented with specific symptoms of acute hydrocephalus 
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such as headache, emesis, and altered visual and/or status. Current recommendations are 
screening every two years in individuals over the age of 21 [Campen; Leung; Sparagana]. 
Infantile spasms, partial motor and generalized tonic clonic seizures are present in 80-
90% of individuals [Sparagana; Kandt, 2003]. Seizures are typically managed with epileptic 
medications. For some, surgical resection allows a favorable long-term outcome [Romanelli]. 
Consistent with other features of TSC, there is a spectrum of severity in intellectual 
dysfunction and behavioral disturbances. Approximately 50% individuals have intellectual 
disability [Kandt, 2003]. Most, but not all mentally retarded children with TSC have seizures. 
Conversely, many patients with TSC have seizures but not mental retardation [Leung; 
Sparagana; O’Callaghan]. In general, an earlier onset of seizures, particularly infantile 
spasms, confers a greater risk of intellectual disability [Prather]. Of note, earlier treatment is 
associated with a better prognosis for learning development and seizure termination. One 
small study found a seizure free status in 50%, normal or borderline mental development in 
30%, and no mental retardation in ten children with an early diagnosis treated with vigabatrin 
followed long-term [Bombaradiere]. 
There are often specific learning difficulties in children with TSC. It is estimated that 25 - 
50% of children with TSC have a diagnosis within autism spectrum disorder [Northrup]. 
Additionally, frequent behavioral disorders include attention deficit disorder, aggressive and/or 
self-injurious behavior, hyperactivity, and sleep problems [Curatolo; Prather]. These may occur 
in combination or as isolated problems [Leung; Roach]. 
Renal manifestations 
The renal manifestations of TSC are the second most common cause of early death 
[O’Hagan]. Angiomyolipoma (AML), the most common renal finding, is present in 
approximately 70% of individuals. AMLs are often bilateral and progressively increase in size 
and number. As the name implies, these growths are comprised of blood vessels, smooth 
muscle cells, and adipose tissue [Henske]. Some degree of gender predilection exists in that 
females are affected 3 to 4 times more often than males [Leung].  
The second most common renal lesions are cysts, affecting approximately 50% of 
individuals [Dixon]. Similar to AMLs, these may increase in size, and are usually numerous. 
Cysts over 4 cm in diameter are often symptomatic and visible on CT scan [Roach, 2004; 
Leung]. Individuals with a contiguous gene deletion involving TSC2 and PKD1, the gene 
responsible for autosomal dominant polycystic kidney disease (ADPKD), will show symptoms 
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of ADPKD such as hypertension, flank pain, and pyelonephritis, and are at increased risk for 
end stage renal disease [Franz].  
Lastly, renal cell carcinoma occurs in less than 2-3% of individuals, at an average age of 
28 [Kwiatkowski, 2005; Patel]. The growth rate of carcinoma is much slower in TSC [Leung].  
Ophthalmologic Abnormalities 
Up to 75% of individuals with TSC have ocular findings. The most common finding is 
retinal hamartoma, present in 40-50% of individuals. One-third of these patients will have 
bilateral lesions [Leung].Lesions are best identified with pupil dilation and ophthalmoscopy. 
The majority of lesions are asymptomatic, though they could lead to visual impairment if large 
enough [Leung]. 
Cardiac Lesions 
The most common cardiac manifestation in TSC is cardiac rhabdomyoma, present in 66% 
of newborns.  The maximum growth period occurs at 22-26 weeks gestation and thus is often 
visualized in the third trimester of pregnancy. After infancy, these lesions are usually 
asymptomatic and gradually disappear over time. Rarely, they result in outflow obstruction 
(requiring surgery), valvular dysfunction, or arrhythmia [Leung].  
Pulmonary Disease 
In TSC, overall pulmonary dysfunction is infrequent. However, the most common finding, 
lymphangioleiomyomatosis (LAM), may develop in up to 39% of women with TSC, typically at 
ages 20-40 [Moss; Roach, 2004]. LAM is thus a well-established gender-specific manifestation 
of TSC and mutations in TSC have been found in individuals with sporadic LAM [Carsillo]. 
Common symptoms of pulmonary disease include cough, dyspnea, hemoptysis, and 
pneumothorax [Roach, 2004]. Disease can progress to the need for oxygen therapy and/or 
lung transplantation.  
Less commonly affected systems 
A lesser known vascular manifestation of TSC involves aneurysm in the descending aorta, 
primarily in the abdominal aorta [Cao]. Though rare, they occur more commonly in children 
under the age of 5 years (the youngest reported at 4.5 months) and impart a risk for premature 
death. Molecular correlation has identified at least one patient with a TSC2 mutation; 
subsequent work in Tsc2 haploinsufficient mouse models demonstrated proliferation of smooth 
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muscle cells and reduced expression of contractile proteins [Cao]. The naturally occurring 
“Eker” rat harbors a Tsc2 mutation and can develop pituitary adenomas, uterine leiomyomas, 
splenic hemangiomas, lesions in the brain resembling SENs, cortical tubers, and renal tumors 
[Wilson].  
Also unappreciated is the extent of gender predilection in specific manifestations. AMLs 
are more common in women with TSC in general, but also in women with TSC-associated 
LAM compared to those with sporadic LAM. Estrogen and progesterone are thought to be 
important in the development of these lesions. Additional effects of sex hormones or 
reproductive manifestations in TSC are poorly understood. Perhaps further examination of 
other possible organ manifestations will lead to the identification of newly appreciated 
aspects of TSC.   
Management 
The severity of TSC is quite variable, and prognosis is based on each individual. As there 
is no cure for TSC, management and surveillance are dependent on the symptoms present 
and function to improve the patient’s quality of life. Routine evaluations include EEG to 
manage seizures, cranial CT/MRI, renal ultrasonography and/or CT/MRI, echocardiography 
when cardiac symptoms are present, behavioral evaluations, and chest CT if pulmonary 
symptoms are present [Leung]. Recommended surveillance includes:  
Individual Surveillance Frequency 
Children/adolescents Cranial CT / MRI 1-3 years 
Individuals with no previously identified renal lesions Renal ultrasound 1-3 years 
Individuals with AML <3.5-4.0 cm Renal ultrasound Semiannually 
Large / numerous renal tumors Renal CT/MRI As needed 
Seizure management EEG As needed 
If cardiac symptoms exist Echocardiography As needed 
If pulmonary symptoms exist Chest CT As needed 
Children entering school / in response to concerns 
Neurodevelopmental 
evaluations 
As needed 
As visual loss is uncommon, routine ophthalmologic evaluations are unnecessary for the 
majority individuals with retinal lesions 
Routine dermatological evaluations are unnecessary for most individuals. 
Source: GeneClinics 
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Inheritance  
TSC is an autosomal dominant condition. Affected individuals have a 50% risk with each 
pregnancy to have an affected child. Approximately one third of children diagnosed with TSC 
have an affected parent while a majority (approximately two thirds) occur as a result of a de 
novo mutation [Sancak; Rose]. TSC-causing mutations are fully penetrant, though TSC shows 
marked variable expressivity within families and among individuals. Thus it is recommended 
that the parents of a child with no family history of TSC be thoroughly evaluated. Some 
individuals often have a very mild phenotype and/or could have eluded recognition from a 
health care provider. The recurrence risk for parents with an affected child but no apparent 
family history is complicated by somatic mosaicism [Verhoef].  
Molecular Genetics  
The TSC1 gene is located on the long arm of chromosome 9 (9q34) [van Slegtenhorst]. It 
encodes the protein hamartin. Almost all TSC1 mutations are truncating. Over half are small 
deletions and insertions, and 40% are nonsense mutations. Splice site mutations have also 
been described; large deletions and missense mutations are rare [LOVD, TSC1]. Recently, 
deletions in the promoter of TSC1 were identified by MLPA [Ouweland]. The TSC2 gene is 
located on the short arm of chromosome 16 (16p13.3) and encodes for the protein tuberin 
[European Consortium]. The majority of TSC2 mutations (64%) are small deletions and 
insertions, splice site mutations, and nonsense mutations. Approximately 28% are missense 
mutations, and the remaining 8% are due to large deletions or rearrangements; 3.7% involve 
the PKD1 gene [LOVD, TSC2]. 
Approximately 20% of mutations identified occur in TSC1 and 60% in TSC2 [Crino]. The 
remaining 20% of individuals have no identifiable mutations. There is a reportedly high rate of 
somatic mosaicism in TSC, estimated between 10% and 25% [Verhoef]. However, a recent 
study used deep sequencing analysis to identify mutations in affected individuals with possible 
low-level mosaicism and concluded the rate of somatic mosaicism may be overestimated and 
actually as low as 6% [Qin].  
DNA testing is available clinically, but is not necessary for a diagnosis of TSC. Studies 
have demonstrated an overall mutation detection rate as high as 85% in patients with a clinical 
diagnosis [Sancak; Kwiatowski, 2010]. The majority of mutations in TSC1 can be detected 
through sequence analysis. In general, the overall detection rate of TSC1 mutations is 30% 
and 15% in familial and simplex cases, respectively.  Sequence analysis of TSC2 has a 
detection rate of approximately 50% in familial cases and 60-70% in simplex cases. 
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Deletion/duplication analysis comprises an additional 0.5% of familial cases, and 5% of 
simplex cases [Northrup]. The detection of large deletions requires additional techniques, such 
as Southern analysis or array comparative genomic hybridization (CGH).  
Several studies have shown genotype and phenotype correlations [Au; Sancak]. TSC2 
mutations are known to result in a more severe phenotype than TSC1 mutations and are more 
common in individuals with de novo mutations. Familial TSC2 mutations and individuals with 
de novo TSC1 mutations have a milder phenotype. Lastly, individuals for which no mutation 
was identified also had milder phenotypes. In spite of these genotype-phenotype correlations, 
mutational analysis should not currently be used for prognostic prediction [Jansen].  
Pathogenicity  
Hamartin and tuberin function as tumor suppressors. The pathogenesis of TSC involves 
both the “two hit hypothesis” as well as haploinsufficiency. The former involves a loss of 
heterozygosity (LOH). Complete loss of either TSC1 or TSC2 leads to a cellular loss of tumor 
suppression and unregulated cell cycle progression, resulting in uncontrolled growth and the 
development of hamartomas [Castro; Jozwiak].  A somatic “second-hit” mutation has been 
best described in renal lesions, and LOH has also been observed in advanced stages of 
murine renal lesion progression [Osborne Wilson]. The TSC genes have also been implicated 
in individuals with sporadic lesions. In an analysis of AMLs taken from women with sporadic 
LAM, TSC2 LOH was detected in six of seven AMLs [Niida]. 
Haploinsufficiency may be another explanation for the developmental of lesions. 
Observations of renal tubules in mouse lesions have indicated a loss of heterozygosity (LOH) 
in only about 20% of lesions, suggesting that haploinsufficiency may be sufficient to lead to 
their development [Wilson]. As LOH is seen less frequently in cortical lesions, some have 
proposed haploinsufficiency to explain the formation of some cortical lesions.  
Hamartin and Tuberin form a biochemical complex that acts as a major regulator of cap-
dependent translation in response to growth factors, energy status, oxygen tension and 
mitogenic signals [Rosner]. This translational inhibition occurs at the level of the mTORC1 
kinase, a key enzyme that controls the activation of multiple proteins of the translational 
apparatus. The TSC complex inhibits mTORC1 through the GTP-ase activating domain of 
tuberin on the RHEB protein, preventing mTORC1 mediated translation and cellular growth 
(Figure 1) [Tee; Castro; Wang].  
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Figure 1. TSC and mTORC1. The TSC1/2 complex forms a heterodimer and inhibits 
mTORC1 (bar), down-regulating cellular translation, cell growth, and proliferation.  Separately, 
mTORC1 is also inhibited by the action of PTEN. In contrast, AKT enhances mTORC1 activity 
(arrow). 
 
Separately, the TSC complex directly binds a second enzyme, mTORc2. This results in 
the phosphorylation and activation of Akt [Tee; Castro]. As Akt is an oncogene implicated in 
cancer formation, promoting such activity is a seemingly curious role for tumor suppressor 
genes [Vivanco]. It is plausible that mutations in the TSC genes could accelerate tumor growth 
through a loss of negative regulation on mTORc1, while a simultaneous loss of mTORc2 
activity may attenuate Akt and could prevent hamartomas from becoming malignant [Huang]. 
Of note, mTORC1 is rapamycin-sensitive and responds to nutrients and energy inputs, and 
mTORC2 is rapamycin-insensitive [Dann; Huang]. The potential for effective symptom 
alleviation in TSC patients with rapamycin treatment is being explored [Koenig].  
 
Mouse Models 
Any organ system could potentially be affected by TSC.   The use of conditional mouse 
models has been important for the study of the roles of the TSC genes in TSC pathogenesis 
and normal organ function [reviewed in Kwiatkowski, 2010].  Adkihari, et al., have examined 
the role of Tsc1 and Tsc2 in the mouse ovary, an organ not thought to be affected in humans 
 
TSC1 TSC2 
mTORC1 PTEN AKT 
- Translation 
- Cell Growth 
- Proliferation 
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with TSC.  They created mice devoid of either Tsc1 or Tsc2 exclusively in the ovaries 
[Adkihari, 2009, 2010].  These ovarian –specific knockout mice demonstrated premature 
activation of primordial follicles and subsequent depletion of the ovarian reserve in young 
adulthood, leading to infertility.  In essence, these animals experienced the equivalent of the 
disorder termed in humans as premature ovarian failure (POF).   
These Tsc1 and Tsc2 ovarian specific knockout mice also showed sub-fertility; each 
produced an average of 2 litters, significantly less than control mice with normal ovarian TSC 
expression. The mice became infertile in young adulthood. Of note, despite accelerated 
activation of primordial follicles, the size of the litters was unaffected.  
The increase in follicular activation from loss of TSC function was associated with 
increased mTORC1 activity, as demonstrated by increased phosphorylation of two 
downstream substrates, p70 S6 kinase 1 (S6K1) and ribosomal protein S6 (rpS6). 
Furthermore, treatment with the mTORC1 inhibitor, rapamycin, reversed the over-activation of 
primordial follicles in knockout mice.  Another ovarian specific knockout mouse model further 
supports a crucial role for mTORC1 in ovarian biology.  In mice lacking the expression of Pten, 
a suppressor of mTORC1 upstream of the TSC complex (Fig 1), the entire primordial follicle 
pool was activated and depleted in early adulthood, features of murine POF consistent with 
the Tsc1 and Tsc1 ovarian specific knockouts.  These results indicate elevated mTORC1 
activity is the driving force of follicular activation, and that proper suppression from the TSC 
heterodimer or other suppressors of mTORC1 activity is necessary to regulate appropriate 
activation, maintaining dormancy of the follicular pool and preserving reproductive function.  
These animal studies suggest that abnormal mTORC1 regulation might contribute to human 
POF, a condition which remains largely idiopathic.    
  
Premature Ovarian Failure (POF) 
The studies discussed above indicate a crucial function of the TSC genes, and mTORC1 
regulation, in murine ovarian function, but the extent to which human ovaries may be affected 
from mutations in TSC1 or TSC2 is unknown. The authors concluded the knockout mice 
underwent the phenotypic equivalent of POF. In humans, POF is defined as the cessation of 
menses in a woman under the age of 40 and displays a clear disruption in the normal human 
reproductive lifespan [Rebar, 2008]. Although widely used in the literature, the term POF may 
be inaccurate, as it indicates a finality of menstrual functioning and fertility that is not 
consistently observed. Other terms such as premature ovarian insufficiency, or POI, have 
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been suggested, to account for a decline in ovarian reserve, and irregularities in menstrual 
functioning concomitant with rising levels of FSH and reproductive symptoms such as hot 
flashes [Rebar]. For the purposes of this reading, the term POF will be used throughout as a 
term to refer to declining ovarian reserve, with the caveat that POI may indeed be more 
representative of the menstrual issues subsequently discussed, particularly in the presence of 
self-reported data and limited facts obtained in this study.  
Ovarian function 
The progression of a woman’s reproductive function begins prenatally, when millions of 
follicles develop and are arrested at meiosis I in the developing gonads of the fetus [Altchek]. 
After reaching a maximal number of about 7 million at approximately 28 weeks, a decline of 
follicles begins. At birth, 1-2 million follicles remain, declining further to approximately 200-300 
thousand at menarche, less than 10% of the original supply. After menarche, a highly 
regulated, cyclic process of ovulation is observed. At the age of 40, most women have about 8 
thousand follicles remaining [Altchek]. This process continues until menopause, occurring at 
an average age of 51 years.  
Beyond the well described feedback mechanisms involving the hypothalamus, pituitary 
gland, and ovaries, the oocyte itself governs a significant portion of ovulation in response to 
highly controlled regulation of activation and development. However, as evidenced by the 
previously mentioned mouse knockout studies, the mechanisms that govern the growth and 
recruitment of follicles are poorly understood. The maintenance of dormancy in the ovaries is 
required for the preservation of the follicular reserve; similarly, appropriate activation ensures 
proper ovarian function, allows for pregnancy, optimal hormonal regulation, and ultimately, 
ovarian senescence at menopause.  
In each menstrual cycle, only one or two eggs are released during ovulation for the 
approximately 40 years of reproductive lifespan. The majority of the remaining oocytes do not 
reach a mature state, or are “recycled.” Thus, one can actually consider atresia the norm, and 
ovulation a rarity. The rate of follicular atresia appears to increase with age. However, it is not 
known whether increasing numbers of follicles undergo atresia prior to activation and growth, 
accelerating the decline in follicular reserve, or if increasing numbers of follicles enter the 
growth phase and thus undergo degradation in the absence of ovulation [Hansen]. Previously 
the rate of follicular decline was thought to increase dramatically after age 38, when 
approximately 25,000 follicles remain [Faddy]. This parallels the decline of fertility, which 
peaks in the 20s and drops off substantially after age 35-38 [Menken]. However, recent 
12 
 
evidence suggests the rate of decline is actually increasing constantly throughout life. 
Therefore both a woman’s initial endowment of follicles and the increasing rate of atresia 
leading to follicular depletion are responsible for a progression toward menopause [Hansen].  
While menopause is a clear, well-defined end to a woman’s reproductive lifespan, it is 
preceded by a dynamic process of a decline in ovarian function, occurring over several years. 
These stages may involve sub-fertility, which often escapes detection because of adequate 
and appropriate hormonal secretion [Hansen]. It is estimated that fertility begins to decline 
approximately 10 years prior to the age of menopause, with an average of 41 marking the end 
of fecundity [Murray]. Later, perimenopause occurs; this is a stage characterized by an 
irregularity in menstruation cyclicity and increased gonadotropin levels. Additionally, the 
number of follicles falls below a certain threshold (1000-1100) [Faddy]. Fertility is 
compromised as many remaining oocytes contain chromosomal aberrations and make a 
viable conception difficult. Eventually, there are no remaining follicles to allow for ovulation, 
and menopause occurs.  
 
Clinical Presentation and Diagnosis 
The most common scenarios for POF evaluation include sub-fertility and menopausal 
symptoms. Difficulty in conceiving often brings women to the attention of health care providers, 
in the setting of an infertility specialist, obstetrician-gynecologist, or reproductive 
endocrinologist. Others present with the onset of menopausal symptoms, including hot 
flashes, dyspareunia, night sweats, and vaginal dryness [Altchek]. In particular, hot flashes are 
a characteristic symptom of POF and are distinguished by their brevity, with an average 
duration of 3.5 minutes. The hypothalamus senses a perceived discrepancy in set and core 
temperature and quickly triggers homeostatic heat loss through increased heart rate, 
perspiration, and vasodilation. In the general population, 85% of women overall will experience 
hot flashes, 30% within three years of menopause [Kronenberg].  Additional indications include 
oligomenorrhea, absence or regression of sexual secondary characteristics, ceasing birth 
control pill without resolution of menstrual cyclicity, or after giving birth [Nippita]. 
Once POF is suspected, the clinician often pursues diagnostic testing such as a 
progesterone challenge to distinguish between anovulatory states and hypothalamic 
suppression [Rebar; Nelson, 2005]. Measurement of serum gonadotropin levels may also be 
indicated. FSH and LH are elevated in POF, but must be measured on separate occasions at 
least one month apart, as fluctuations in levels from intermittent ovarian activity can mask 
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underlying disruptions [Shelling]. In addition, estrogen levels are typically low, approximately 
50 pg/ml in women with an absence of functional follicles [Rebar]. Naturally, other reasons for 
a lack of menstruation, such as pregnancy, thyroid abnormalities, polycystic ovarian 
syndrome, and elevated prolactin must be excluded [Shelling; Rebar]. Lastly, a thorough 
history is imperative in determining an etiology for POF, which is considered idiopathic for the 
majority of women [Goswami, 2005]. A value of FSH over 40 IU/ml with concomitant 
amenorrhea for 3-6 months (variable among physicians) is consistent with a diagnosis of POF 
[deVos; Shelling]. 
 
Epidemiology 
POF affects about 1% of the US population [Rebar]. The estimated prevalence increases 
by a factor of about 10 with each decade of life, ranging from 0.1% at age 30 to 1% at age 40 
[Rebar]. Some ethnic disparities exist: there appears to be a higher prevalence (1.4%) in 
African-American and Hispanic women; the prevalence in Caucasians is about 1%; the lowest 
figures, 0.1and 0.5%, are in Japanese and Chinese women, respectively [Nippita]. 
 
Etiology 
In hypothesizing possible mechanisms of early ovarian decline, one appreciates the 
complexity of the menstrual cycle. The time period for a primordial follicle to progress through 
activation from dormancy, further follicular development, and selection for ovulation, atresia, or 
rescue varies dramatically from days to decades [Altchek]. Additionally, there are many stages 
of folliculogenesis or ovulation from which a depletion of significant magnitude may hasten the 
progression to menstrual cessation. First, as early development of primordial follicles to 
primary and pre-antral follicles occurs with each cycle, a smaller initial number of primordial 
follicles to begin with would deplete the supply sooner. Atresia occurs concurrently at each of 
these stages, resulting in a decreasing number of developing follicles maturing toward 
ovulation. Thus, any increase in the rate of atresia will parallel the rate of decline in the 
follicular supply.  Thirdly, follicles must mature from the antral stage toward ovulation. Errors or 
alterations in signaling, secreted factors, gonadotropin receptors, or numerous supporting 
granulosa and thecal cells could all lead to ovarian dysfunction and early ovarian failure [Laml, 
Persani]. Lastly, follicular damage or destruction from autoimmune factors or toxic effects from 
excess metabolites could preclude successful follicle maturation [Nelson, 2009]. 
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Studies of POF have been hindered by the inaccessibility of the ovary and by the 
occurrence of follicle depletion before symptom onset. A direct cause of POF remains 
unknown in about 90% of cases [Nelson, 2009]. Broadly speaking, established etiologies 
can be categorized into genetic conditions, autoimmune disease, exposures, postsurgical 
complications, and other causes, and will be discussed below. [Strauss; Gravholt; Hundscheid; 
Goswami; Laml].  
Genetic 
It is of no surprise that mutations in genes encoding proteins for the functions mentioned 
above would be found in women with reproductive dysfunction. In fact, many mutations have 
been found in small samples of women with isolated POF. Variants in gonadotropin receptors, 
GDF9, NOBOX, NR5A1, Inhibin, FSH, POLG, AIRE, and FIGLA have been reported at low 
frequencies [Laml; Persani]. 
Though comprising a small proportion of POF, the additive effect of genetic causes 
accounts for approximately 5% of POF etiology [Shelling; Persani].  By far the largest part of 
this is due to errors in the X chromosome.   
Each female has two X chromosomes. Through a modification known as X-inactivation, 
one X chromosome is effectively silenced in each cell. Studies have shown that while 
differentiation of ovaries requires only one X chromosome, genes on the second X 
chromosome function in ovarian maintenance [Laml]. Some regions of the X chromosome 
accordingly “escape” inactivation and may be crucial for ovarian function, as evidenced by 
POF and amenorrhea in women with breakpoints or deletions on the X chromosome including  
Xp11.2-p22.1, Xq26-28, Xq13-22 [Laml; Conway]. It follows that global aberrations of the X 
chromosome would be implicated in ovarian dysfunction, and indeed are present in 40-50% of 
girls with primary amenorrhea and a portion of women with reproductive dysfunction. This 
includes structural rearrangements such as translocations, mosaicism of sex chromosome 
dosage, and aneuploidy such as Turner syndrome or triploidy.  
Specific mutations in genes on the X chromosome can also lead to POF, the most well-
known being Fragile X syndrome. This is an X-linked mental retardation syndrome and the 
most common cause of mental retardation in boys. Abnormal expansions of a CGG repeat in 
the promoter regions of the FMR1 gene lead to abnormalities in gene methylation and gene 
silencing. The inactivating expansion occurs when an allele containing between 55 and 200 
CGG repeats is inherited from the mother [Chonchalya]. These intermediate sized alleles are 
termed “premutation,” and carrier females have an absence of cognitive disease but an 
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increased risk to pass on an expanded allele and have an affected boy [Corrigan]. The 
frequency of POF in premutation carriers is estimated at 11.5% in those with a family history of 
POF, and 3.2% in those with sporadic POF [Rohr]. 
The mechanism behind the increased frequency of POF in premutation carriers is 
unknown, but is hypothesized as similar to that of Fragile X-related tremor/ataxia syndrome, a 
neurological disorder that may present in premutation carriers. Expanded CGG repeats in the 
5’ untranslated region of the gene shift the transcription start site upstream. A 5-fold elevation 
of FMR1 mRNA may result in a toxic gain of function from a buildup of abnormal gene 
products. It may lead to excess binding of proteins to the expanded repeat region, further 
altering the translational efficiency; protein levels (FMRP) are known to decrease with 
increasing repeat size [Hagerman]. Some have proposed that a cumulative effect of toxic RNA 
may lead to increases in follicular atresia, leading to POF. Alternatively the FMRP-regulated 
translational suppression on a subset of mRNA could lead to haploinsufficiency of proteins 
needed in oocyte development [Rohr].  
A diagnosis of POF, especially with a significant family history, warrants exploration of the 
possibility of Fragile X. A 2006 statement from ACOG recommends that in a woman with 
ovarian failure or elevated FSH level of unknown cause before 40 years “fragile X carrier 
screening should be considered to determine whether she has a premutation” [ACOG].  
More recently, chromosomal microarray has been utilized to identify copy number 
variations in affected individuals. A recent study identified 44 losses and gains potentially 
causative for POF in 74 patients. Many of the candidate genes are involved in meiosis, DNA 
repair, and folliculogenesis or male fertility in homologs of model organisms [Ledig]. 
Autoimmune  
Autoimmune disease contributes another significant portion of causes and may be present 
in 10-20% of women with POF, often correlated with adrenal disease [Shelling]. These include 
Addison’s disease, hypoparathyroidism, diabetes mellitus, pernicious anemia, vitiligo, 
myasthenia gravis, autoimmune polyglandular syndrome types I and II, Crohn’s disease, 
Sjogren’s syndrome, and systemic lupus erythematosus [Nippita].  
Exposures 
Radiation and chemotherapy for the treatment of malignant disease is one of the leading 
causes of POF [Nippita; Rebar]. Chemotherapy depletes the number of oocytes, and affects 
the structure and function of oocytes and granulosa cells. The risk to develop POF from 
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radiation therapy is primarily from treatment within the pelvic area, but disruptions in the 
hypothalamic-pituitary-ovarian axis must be considered. Of note, an additional factor of 
importance involves the age at which radiation therapy occurs; prepubertal ovaries are fairly 
resistant to radiation. Secondly, there is a dose-dependent effect, and the greatest risk for 
ovarian failure occurs at doses of radiation 9 grays or higher [Nippita; Rebar]. Infection is 
another possible cause of ovarian depletion. A study in 1998 demonstrated that 3.5% of 
women with POF had varicella, shigella, or malaria exposure. In addition, some women may 
develop oophoritis during an exposure to mumps [Goswami]. Other exposures leading to POF 
may include surgeries, particularly in the pelvic region, that carry the potential to disrupt 
vascular supply to the ovaries. 
Other 
Several reported associated causes of POF include cigarette smoking, epilepsy, 
endocrine disruptors, and other environmental exposures, though these are equivocal and 
poorly studied [Goswami; Conway]. Exposures to industrial 2-bromopropane, a cleaning 
solvent, was associated with primary ovarian insufficiency in 16 Korean women [Nelson, 
2000]. 
Management  
The management of POF involves a combination of medical and psychological 
assistance. A negative, often traumatic psychological impact has been consistently reported in 
the literature, including social anxiety, depression, and lowered self-esteem [Rebar; Nippita; 
Shelling; Schimdt; Liao; Groff; deVos]. Many women experience frustration from an inability to 
recognize clinical reasons for their symptoms; one study found it took up to 5 years for a 
diagnosis in a quarter of affected women [Albuzaidi]. Secondly, the term “failure” alone can 
bring feelings of inadequacy and guilt [Nelson, 2005]. Indeed the rates of depression in women 
with a diagnosis of POF seem to be higher than the general population. A recent study in 174 
women with sporadic POF found the onset of depressive systems seemed to occur prior to the 
actual diagnosis of POF but after the onset of symptoms [Schmidt].  
It has been suggested that the term POF is inadequate to reflect the spectrum of ovarian 
dysfunction, uninformative and difficult for patients, and to some degree, inaccurate [deVos; 
Shelling; Rebar]. For example, in three studies, 50%–84% of women with POF had new follicle 
growth and 16%–49% ovulated [Welt]. The term “primary ovarian insufficiency” is also used by 
clinicians and was in fact the original term coined in 1942 by the endocrinologist Albright Fuller 
[Rebar]. It is a vague term that allows for the heterogeneity and possible irreversibility of 
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disease, and does not imply finality [deVos; Shelling; Rebar]. Additional terms include 
“hypergonadotropic amenorrhea,” “hypergonadotropic hypogonadism,” and “primary 
hypogonadism.” These terms may be less recognizable to patients, but also account for 
etiologies outside of a defect in the ovaries [Shelling; Rebar].  
A third psychological factor involves women who are seeking pregnancy at the time of 
diagnosis. As increased numbers of women delay childbirth, the age of which childbearing is 
most desired may be concurrent with the onset of POF [Shelling].  Estimates of the percentage 
of women with POF who may still become pregnant range from 5-10% [Shelling]. However, 
there are no known reliable predictors to identify these women, nor are there specific identified 
measures to increase the chances of conception [deVos]. In fact, ongoing assessments of 
patients have found that women with no oocytes observed by imaging have become pregnant, 
while women with residual ovarian function have not [Dr. Michael J. Heard, personal 
communication]. There is recent evidence that conception may occur with the suppression of 
gonadotropin-releasing hormone (GnRH) analogues and subsequent ovulation induction, but 
no published trials exist [deVos]. The lack of prognostic information makes it difficult for 
clinicians to offer definitive information to women, and frustrating for patients who face the 
possibility that they may not conceive.  
The low chance of success in using a patient’s own oocytes for conception usually 
prompts discussion of other pregnancy options for those women who desire children. Adoption 
is certainly a choice for many families. More commonly, the use of donor eggs is utilized and 
studies show higher success rates than those observed in traditional in vitro fertilization 
[Rebar]. Appropriate counseling on familial risks of POF is essential, as many women choose 
to have a family member, such as a sister, donate oocytes. Approximately 20-30% of women 
have a family history of POF [Woad].  
Additional management for patients involves mitigating the risks to the patient from a lack 
of estrogen, which is important for bone health and reducing the risk of adverse cardiac 
events. In studies of women with natural early menopause, the risk of mortality from 
cardiovascular events was significantly higher than in women with late menopause, suggesting 
that longer exposure to endogenous estrogen may be protective against cardiovascular 
disease [van der Schouw]. A study of women with primary ovarian insufficiency demonstrated 
a change in the lipid profile of patients, including elevated triglycerides and lower HDL 
cholesterol concentrations [Knauff].   Evidence from longitudinal studies such as the Women’s 
Health Initiative (WHI) have assessed risks for the development of breast cancer, heart 
attacks, and strokes in menopausal women who had a prior hysterectomy undergoing 
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hormone replacement therapy (HRT) [LaCroix]. There are marked differences in women who 
have experienced natural menopause and patients with POF; the former are typically seeking 
symptom alleviation, while the latter utilize HRT to counteract the deficit of estrogen [Shelling]. 
Recent releases from the WHI have indicated that the risks for breast cancer appear lower in 
those women who received estrogen only after menopause, and younger estrogen users had 
a lower rate of heart attacks [LaCroix]. Estrogen is also important in protection against 
osteoporosis. In the absence of exogenous estrogen supplementation, routine bone density 
scans, medication, and lifestyle changes are useful in preventing osteoporosis and a reduction 
in bone mineral density [Woad; Shelling]. Finally, as autoimmune disorders are considered an 
etiology of POF, approximately 20% of women with spontaneous POF will develop 
autoimmune hypothyroidism [Kim]. Therefore, it is prudent to include measurements of TSH 
and free T4 during a workup for POF, and to check for the presence of serum thyroid 
peroxidase autoantibodies [Nelson, 2009]. 
Despite the mechanisms of POF identified through numerous studies among various 
medical disciplines, diagnosis includes a direct cause in only a small portion of women. This 
fact necessitates further attempts to understand disruptions to ovarian function, and the 
eventual establishment of risk factors to identify women for which further attention is 
implicated. 
Goals of Project 
As the majority of women are given a diagnosis of idiopathic POF, many are left with little 
guidance on appropriate management and information for family members [Altchek]. 
Therefore, more information and research is necessary to pinpoint specific mechanisms of 
POF in humans and identify possible genetic components to account for the relatively high 
observed familial associations. Until recently there was no evidence to suggest the TSC genes 
were crucial for follicular recruitment, survival, maturation, or demise. Recent evidence from of 
Tsc1 and Tsc2 conditional knockout mouse models suggests otherwise. Identifying a possible 
association between ovarian dysfunction and TSC-causing mutations is thus an appropriate 
endeavor. The simplest way to assess the possibility of a connection between the TSC genes 
and POF is to sample a selection of women with Tuberous Sclerosis Complex, since the 
majority harbor a mutation in either TSC gene. Determining if an association between the two 
conditions exists will shed more light on the function of the TSC genes and their possible 
pathogenic role in the ovaries, and about mechanisms behind the pathogenesis of POF in 
women. There is currently no evidence to suggest women with TSC have a higher incidence of 
POF compared to the general population, or that the TSC1 and TSC2 genes play a similar role 
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in human ovaries as was demonstrated in the mice [Adkihari]. The aim of this project is 
establish a prevalence of POF and associated reproductive dysfunction in a sample of 
women with TSC. We hypothesize that no significant association exists between women 
affected with TSC and the likelihood of developing POF. Thorough self-reports of menstrual 
function, reproductive history and symptoms, as well as clinical manifestations of TSC will be 
collected from individuals. Expert medical guidance will be useful in determining which women 
may have an unlikely, possible, or probable diagnosis of POF, or features pointing to perhaps 
an occult and as of yet unrecognized problem. In the absence of a defined control population, 
current scientific literature will be used to compare these women to what is reported about 
POF in the general population. This information will allow for more interpretation of the results 
of the conditional knockout mice studies, and further insight into possible roles of these genes 
in human ovarian function.  
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Materials and Methods 
Participants 
Participants were woman with tuberous sclerosis complex over the age of 18 who are 
members of the national Tuberous Sclerosis Alliance (TSA) support group.  This study, HSC-
GSBS-10-0329, was granted exempt status by the University of Texas Health Science Center 
Committee for the Protection of Human Subjects.  A total of 1000 questionnaires in return 
addressed envelopes were sent to the TSA.  These were sent to randomly selected women 
from a database maintained by the TSA. Identifying information was only available to 
members of the TSA and questionnaires were returned in blank, preaddressed envelopes. 
Approximately one-fourth of the women to whom the questionnaire was sent were 
“dependent,” meaning they are entered in the TSA database as individuals who live under the 
care of another individual and thus the questionnaire was completed by a caretaker or family 
member. We received a total of 200 questionnaires; five were blank, twelve were completed 
with respect to an individual who was under the age of 18, and one was sent to an affected 
male, giving a final sample size of 182. These individuals were excluded from analysis. An 
email address was created in the event that women may have questions; one response was 
received regarding the appropriate female in the household to complete the questionnaire. A 
telephone number was also provided, and two women did make contact with questions and 
concerns about the questionnaire; no information from email or telephone correspondence 
was kept.  
Questionnaire Design  
 The questionnaire was developed to encompass three areas: demographic 
information, reproductive health and history, and information about the individual’s history of 
TSC. In the absence of access to validated questionnaires assessing POF and without clinical 
information from respondents, the questionnaire was designed through extensive literature 
review and clinical expertise. Please see Appendix A for a complete questionnaire. A 
description of the questions included in each section follows:  
 Demographics: Independent/proxy respondent, current age, height and weight, 
ethnicity, employment status, marital status, household status, educational level, and annual 
household income. 
 Reproductive Health: Age of menarche, age and number of pregnancies, live births, 
and premature births, number of and ages at miscarriages, and number of terminations; a 
detailed menstrual history from ages 16-40, indicating menstrual cycle regularity and the use 
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of contraception; perimenopausal symptoms, blood tests indicating thyroid disease, elevated 
testosterone levels, or a menopausal state; history and age of radiation therapy, 
chemotherapy, hysterectomy, and/or oophorectomy; diagnosis (age, and by whom) of any of 
the following: POF, polycystic ovarian syndrome (PCOS), Addison’s disease, Autoimmune 
disease, Anorexia, Infertility, Turner syndrome, Galactosemia, Amenorrhea; a family history 
(relation to individual, and age of diagnosis) of Fragile X syndrome, POF, and unspecified 
autoimmune disorders; current medication, dose, and frequency.  
 TSC: Age of diagnosis, family history (relation to individual, and age of diagnosis, and 
genetic testing (if pursued, and results, if known); history of a SEGA (type of treatment 
received, if applicable); history of seizures (age of onset, frequency, and if surgery was 
performed for seizure control); current and previous seizure medication (number of years 
taken, and an indication of medication effectiveness on a 1-3 scale);  diagnosis 
(current/previous diagnosis and age of diagnosis) of any of the following: learning disability, 
attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder, depression, dyslexia, 
intellectual disability, obsessive compulsive disorder (OCD), other); clinical manifestations of 
TSC (age of diagnosis, indication of current vs. prior manifestation, where applicable): facial 
angiofibromas, hypopigmented macules, ungual tumors, renal cysts, angiomyolipoma, renal 
cancer, pulmonary cysts, lymphangioleiomyomatosis, shortness of breath, rhabdomyomas, 
and irregular heartbeat. Lastly, an opportunity for women to write in additional comments or 
concerns was provided.  
Menstrual Classification  
Menstrual regularity was defined as 10 or more periods per year. Menstrual irregularity 
was defined as 9 or less periods per year, or 0. Contraception was indicated by use of oral 
contraceptive pills or an intrauterine contraceptive device. Time frames for age ranges of 
menstrual history were divided into the following year increments: 16-20, 21-25, 26-30, 31-35, 
36, 37, 38, 39, and 40. Women reported their history in regards to the majority (more than half) 
of the time in each age range. Time frames in which women reported using contraceptives 
were considered uninformative. For women reporting hysterectomy prior to age 40, only time 
frames prior to the age of their hysterectomy were considered informative. Seven women 
reported oophorectomy without hysterectomy; these were considered to be bilateral as the 
women were no longer menstruating. The information gathered from the responses to the 
menstrual history was classified into the following five categories:  
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Group Classification Number of informative time frames Menstrual regularity 
0 All Regular At least one Regular in all time frames 
1 All Irregular At least one Irregular in all time frames 
2 Regular to Irregular At least two 
Consistently regular in early time frame(s) 
changing to consistently irregular in later 
time frame(s) 
3 Alternating Regularity At least two 
Menses alternate between regularity and 
irregularity, case not classified in Group 2 
9 Unknown None N/A 
      
TSC Classification 
Women reported specific manifestations in several organ systems and these were compared 
to data in the current TSC literature to assess for reliability of data. The following 
classifications were made: 
Category Manifestations 
Dermatological 
Facial Angiofibromas 
Hypopigmented Macules 
Ungual Tumors 
Renal 
Renal cysts 
AML 
Renal Cancer 
Pulmonary 
Pulmonary Cysts 
LAM 
Shortness of Breath with Exertion 
Cardiac Rhabdomyomas Irregular Heartbeat 
Seizure  History of Seizures 
 
Statistical Analysis 
Responses were entered into a password protected Microsoft Access database. 
Descriptive analysis was performed for all variables (frequencies, means, median, range, 
standard deviation, as applicable). All analysis was performed in Stata v.11 (College Station, 
TX). Fisher’s exact t-test analysis was used with a significance p-value of <0.05. 
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Results 
 
Participants and Demographics 
       A total of 200 questionnaires were received for a response rate of 200/1000 (20%). Five 
surveys lacked sufficient information, twelve surveys were completed with respect to 
individuals under the age of 18, and one survey was sent to the household of an affected 
male, resulting in a final sample size of 182. Participants were asked to indicate if the person 
completing the questionnaire was affected with TSC (independent participant), or if they were 
completing the questionnaire with respect to an affected individual (dependent participant). A 
total of 42 women were dependent or this information was missing, and the remaining 140 
were labeled independent. Demographic information for both groups is provided in Table 1. 
The average age of independent participants was 44 years, and 35 years for dependent 
women. The overwhelming majority of the study population (90.1%) indicated their ethnicity as 
Caucasian. Differences in marital status, employment, educational level, and income between 
independent and dependent participants are also provided. All women were presumed to have 
a clinical diagnosis of TSC based upon their membership in the TSA. In spite of this 
involvement, the questionnaire was constructed to further characterize TSC disease of the 
participants.  This data follows the reproductive data. 
  
24 
 
  * “Dependent” includes women for which this information was missing 
 
 
 
Table 1. Demographic information for Independent and Dependent Women with TSC* 
N=182 
 
Age  Independent / Dependent Status 
n (% of total sample)  
Median: 44 years 35 years  Independent 140 (76.9) 
Range: 18 – 77 years 18 – 68 years  Dependent/ Unknown  42 (23.1) 
 
 
Dependent 
Women 
Independent 
Women    
Dependent 
Women 
Independent 
Women  
 n (% of 42) n (% of 140)   n (% of 42) n (% of 140) 
 
Ethnicity 
 Employment Status 
Caucasian 34 (81.0) 130 (92.9)  Unemployed 29 (20.1) 20 (48.8) 
African-
American 3 (7.1) 3 (2.1)  Part-time 14 (10.0) 6 (14.6) 
Hispanic 0.0 1 (0.7)  Full-time 64 (45.7) 4 (9.8) 
Asian 2 (4.8) 1 (0.7)  Student 6 (4.3) 2 (4.9) 
Other 3 (7.1) 5 (3.6)  Disabled 10 (7.1) 6 (14.6) 
    Retired 10 (7.1) 1 (2.4) 
    Other 7 (5.0) 2 (4.9) 
   
Marital Status 
 Annual Household Income 
Single 37 (26.4) 37 (88.1)  < $10,000 8 (6.6) 13 (37.0) 
Married 82 (58.6) 4 (9.5)  $10,000 – 24,000 12 (9.8) 8 (22.9) 
Divorced 16 (11.4) 1 (2.4)  $25,000 – 49,000 25 (20.5) 3 (8.6) 
Widowed 5 (3.6) 0.0  $50,000 -74,999 20 (16.4) 3 (8.6) 
    $75,000-99,999 21 (17.2) 2 (5.7) 
    > $100,000 16 (13.1) 1 (2.9) 
    Decline / blank 38 (27.1) 12 (28.6) 
 
Household Status 
 Highest Education Level 
Alone 22 (15.70) 5 (11.9)  Under 12th grade 3 (2.1) 18 (43.9) 
With family 81 (57.9) 25 (59.5)  Completed 12
th
 
grade 
30 
(21.40) 12 (29.3) 
With S/O 34 (24.3) 4 (9.5)  Some college 43 (30.7) 6 (14.6) 
Assisted 
living 0 (0) 7 (16.7)  Bachelor’s degree 31 (22.1) 4 (9.8) 
Other 3 (2.1) 1 (2.4)  Master’s degree 33 (23.60 1 (2.4) 
 Reproductive History 
      All information obtained in this study was self
unconfirmed by medical chart review. Data are presented in Tabl
separated with respect to independent and dependent women. The study question of interest, 
the prevalence of premature ovarian failure in women with TSC, is presented afterward. 
      The reported average age of 
dependent and independent women
the general population and suggests initial menstrual function is intact in 
women with TSC. Though some degree of pub
of cycles normalize by age 16
years was still considered irregular even if followed by consistently regular cycles. 
Figure 2: Age of menarche of 
      History of menstrual irregularity was determined by self
of oral contraceptives, for five year intervals from 16
Women were asked to report if cycles were regular or irregular for the majority of the time in 
each category. Regular was defined as “
defined as “less than 9 periods a year, or 0.” Oligomenorrhea is consisten
literature as fewer than 9 periods 
into those with only irregular cycles, women progressing from consistently regular to 
consistently irregular periods, women progressing from 
regular periods, and women whose periods alternated between regular and irregular cycles.  
Of 182 women, 36 had a history that was uninformative because of unclear responses and 
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-reported and thus reproductive information is 
es 2 through 10 and 
menarche was 12.5 years and did not differ between 
 (Figure 2). This age at menarche is consistent with that of 
this population of 
ertal irregularity is not uncommon, the majority 
-20. Thus, irregularity reported during the time 
entire sample of Women with TSC
 
-reported cycle regularity, and use 
-35, and one year intervals from 36
10 or more periods in a year,” and irregular was 
tly reported in the 
in one year. Women with some irregularity were then divided 
consistently irregular to consistently 
9 10 11 12 13 14 15 16
Age (years)
Mean: 12.47 years 
 
period of 16-20 
 
 
 
-40. 
17 18
1.6
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oral contraceptive use.  Nonetheless, 57 women (31.3%) displayed some irregularity in 
menstrual cyclicity between the ages of 18 to 40 (Table 2).   
 
Table 2. Menstrual History 
 
Independent 
Women 
N=140 
 
Dependent 
Women 
N=41 
 
All women 
N=181 
Menstrual category n (%)  n(%) n (%) 
   
Always regular 71 (50.7)  17 (41.5) 88 (48.6) 
Always irregular 16 (11.4)  8 (19.5) 24 (13.3) 
Regular to irregular 15 (10.7)  3 (7.3) 18 (9.9) 
Irregular to regular 5 (3.6)  2 (4.8) 7 (3.9) 
Alternating regularity 7 (5.0)  1 (2.4) 8 (4.4) 
Uninformative 26 (18.6)  10 (24.4) 36 (19.8) 
 
Pregnancy  
      Pregnancy data included a history of pregnancy, maternal ages at delivery of all live and/or 
premature births, the number of miscarriages and maternal ages at occurrence, as well as the 
number of voluntary terminations.  92 (50.1%) women indicated that they had become 
pregnant. (Table 3) Of these, there were 10 women who had no live births, while a total of 8 
women had premature births. The average number of pregnancies for women was 1.71, with 
an average age of 25.3 years for the first pregnancy. Lastly, 3 of 18 total women who reported 
a voluntary termination were dependent, and 15 were independent.  
Table 3. Pregnancy 
 
Independent 
Women 
N=140 
 
Dependent 
Women 
N=42 
 
All Women 
N=182 
   
Women pregnant at any time n (%)  n (%)  n (%) 85 (60.7)  7 (16.7) 92 (50.1) 
Average number of live births 1.7 ±1.5  1.3 ± 1.0 1.7 ±1.5 
Average age at first birth 
(years) 25.6 ± 5.5   21.8 ± 2.5  25.3 ± 5.4  
Women who had preterm birth 7  1 8 
Women who had voluntary 
termination 3  15 18  
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Miscarriage 
     Of 92 women who reported ever being pregnant, 38 (41.3%) reported having a miscarriage 
at one point in their life (Table 4). This rate of miscarriage is significantly higher than expected 
when compared to  national estimates from literature and US epidemiological data from 
national surveys, which ranges from 15-25% for aged 25-39 years. Thirty-five of these women 
were independent, and the remaining two did not indicate a dependent or independent status. 
The ages at which the first miscarriage occurred varied from 19 to 40 with a mean of 28.5 
years. The average number of miscarriages women reported was 1.6, ranging from one to six.  
Menstrual history for these women is also provided in Table 4. Of women who had a 
miscarriage, 34.2% had a history of some type of menstrual irregularity, while 50% reported a 
history of consistently regular cycles. Six (17.1%) women with a history of miscarriage never 
experienced a live birth, and 29 (82.9%) women with a history of miscarriage did have at least 
one live birth.  
Table 4. Miscarriage History for Women with TSC Reporting Pregnancy 
N=92 
 
 
 
Women who had at least one 
miscarriage 
n (%) 
38 (41.3) 
Average age of miscarriage (years) 28.5 ± 5.9 
Average number of miscarriages 1.6 ± 1.1 
 
 
Menstrual category 
Women with history of miscarriage 
n (% of women reporting pregnancy) 
Always regular 
 19 (50) 
Always irregular 
 4 (10.5) 
Regular to Irregular 
 3 (7.9) 
Alternating regularity 
 6 (15.8) 
Uninformative 
 6 (15.8) 
 
Reproductive symptoms, tests, and surgeries 
      The questionnaire was designed to screen for symptoms related to menopause, POF, and 
other reproductive disorders, as well as a history of blood tests and surgery related to 
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reproductive issues. We asked women who experienced reproductive symptoms to specify if 
they occurred currently or in the past. We also asked them to specify a duration (in years) for 
which these symptoms lasted (Table 5). We also inquired about blood tests indicating a 
menopausal state, thyroid disease, or elevated testosterone levels (Table 6).  
A surgical history of hysterectomy was reported in 38 women below the age of 40 (Table 7). 
Eight women did not indicate an age at which this was performed, and were not considered 
further as we had no means of evaluating their cycles. Additionally 18 women reported 
oophorectomy at an average age of 42 years. Radiation therapy at unspecified locations was 
reported in six women. One woman indicated use of radiation for SEGA, but the rest did not 
indicate a diagnosis of cancer or other indications. The average age of radiation therapy was 
31.7, reported by three women. One woman reported chemotherapy for an unspecified 
indication, performed at 45 years.  
Table 5. Reproductive Symptoms in Women with TSC Less Than 40 years 
 Independent Women 
 
Dependent Women 
 
All Women 
Symptom 
Current or 
previous 
symptom 
n (%) 
Average 
duration 
(years) 
Current or 
previous 
symptom 
n (%) 
Average 
duration 
(years) 
Current or 
previous 
symptom 
n (%) 
Average 
duration 
(years) 
    
Hot Flashes 7 (14.9) N=47 5.8 ± 4.7  
2 (7.7) 
N=26 2.3 ± 2.5  
9 (12.3) 
N=73 4.9 ± 4.4 
Night Sweats 10 (21.3) N=47 1.2 ± 0.5  
2 (7.7) 
N=26 2.3 ± 2.5  
12 (16.4) 
N=73 1.5 ± 1.2 
Body Hair 8 (17.4) N=46 12.3 ± 6.3   
3 (11.1) 
N=27 15.0 ± 7.1  
11 (15.1) 
N=73 13.2 ± 6.0 
High Blood 
Pressure 
12 (26.0) 
N=46 4.5 ± 3.0  
7 (25.9) 
N=27 12. ± 8.9  
19 (26.0) 
N=73 7.7 ± 6.8 
Milky breast 
discharge, 
excluding 
breastfeeding 
7 (15.2) 
N=46 1.1 ± 1.3  
1 (3.7) 
N=27 --  
8 (11.0) 
N=73 1.1 ± 1.3 
Weight gain 
of 25 pounds, 
excluding 
pregnancy 
17 (35.4) 
N=48 N/A  
9 (33.3) 
N=27 N/A  
26 (34.7) 
N=75 N/A 
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Table 6. Reproductive Blood Tests in Women with TSC less than the age of 40 
 Independent Women 
 
Dependent 
Women 
 
All Women 
Blood Test Indicating: N (%) N (%) N (%) 
Menopausal State 0 (0.0) N=50 
1 (3.7) 
N27  1 (1.3) 
Thyroid Disease 4 (8.0) N=50 
4 (14.8) 
N=27  8 (10.4) 
Elevated Testosterone 
Levels 
3 (6.0) 
N=50 
1 (3.7) 
N=27   4 (5.2) 
 
 
Table 7. Surgical History of Women with TSC  
Women Reporting Surgery Performed at Less Than the Age of 40 
 
 Independent Women 
 
Dependent Women 
Surgery n           
% of 
Independent 
Women  
N=140 
Average 
Age 
(years) 
n 
% of 
Dependent 
Women  
N=42 
Average 
Age (years) 
Hysterectomy 31 (22.1) 35.6 ± 9.7 7 (16.7) 26.6 ± 10.9 
Oophorectomy 14 (10) 41.6 ± 7.4 4 (9.5) 32 ± 5.3 
Radiation therapy 0 -- -- 3 (7.1) 31.7 ± 10.0 
Chemotherapy 1 (0.71) 45 0 -- -- 
 
Other Reproductive Disorders 
      The presence of other reproductive disorders is presented in Table 8.  Eleven women 
reported a diagnosis of PCOS, at an average age of 32.4 years. Features associated with 
PCOS can include menstrual irregularities, elevated BMI, and symptoms such as acne and 
body hair. Additionally, the use of valproic acid is thought to be a risk factor for PCOS, 
particularly in women with an elevated BMI. Twenty-one women reported using valproic acid in 
the past, for an average of 5.33 years. Seventeen women reported current use of valproic 
acid, for an average of 14.8 years. Of the 17 women currently using this medication, one did 
report a diagnosis of PCOS.  Other common disorders among the women were infertility and 
autoimmune disease, present in 13 women each. Of note, 64 independent and 13 dependent 
women in the entire sample indicated a family history of autoimmune disease. The menstrual 
history classifications for these three diagnoses are presented in Table 9. 
30 
 
 
 
 
 
 
Table 8. Reported Reproductive Diagnoses in Women with TSC 
(not otherwise confirmed) 
 
 Independent Women 
 
Dependent Women 
Diagnosis n (%) Average Age Diagnosed n (%) 
Average Age 
Diagnosed 
POF 4 (2.9) N=135 
 
39.3 ± 4.9* 
 
 
0 
N=37 N/A 
PCOS 11 (8.3) N=133 32.4 ± 14.7  
0 
N=38 N/A 
Amenorrhea 10 (7.5) N=134 30.6 ±11.5  
2 (5.3) 
N=38 Unknown 
Infertility 13 (9.6) N=135 30.9 ± 6.0  
0 
N=38 N/A 
Anorexia 5 (3.7) N=135 20.3 ± 1.5  
1 (2.6) 
n-38 13 
Addison disease 1 (0.8) N=134 41  
0 
N=38 N/A 
Autoimmune Disease 13 (9.7) N=134 36.6 ± 15.0  
0 
N=134 N/A 
* One woman indicated an age at diagnosis of 45; this age was excluded 
 
Table 9. Menstrual classifications of common reproductive diagnoses 
 
Menstrual 
Classification 
PCOS 
N=11 
Infertility 
N=13 
Autoimmune 
N=13 
n (%) 
 
Always Regular 4 (36.7) 5 (38.5) 8 (61.5) 
Always Irregular 2 (18.2) 1 (7.7) 2 (15.4) 
Regular to Irregular 0 4 (30.8) 0 
Alternating 
Regularity 2 (18.2) 2 (15.4) 2 (15.4) 
Uninformative 3 (27.3) 1 (7.7) 1 (7.7) 
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Medication 
      Women were asked to list the current medications they were taking, including frequency 
and dosage. The classes of medications are listed in Table 10; we did not have information 
about specific indications for each woman’s prescriptions.  Data on seizure medications are 
presented subsequently. On average 80.8% of women took medications. Outside of 
multivitamins and supplements, the most common medications for independent women were 
analgesics, followed by medications for high blood pressure, and psychiatric illness. For 
dependent women, the most common were those for high blood pressure, gastric reflux, and 
psychiatric illness. 
 
 
 
Table 10. Current Non-Antiseizure Medications 
 
 
Independent Women   Dependent Women 
Number of women 
reporting current 
medication 
111 (79.3%) 
N=140  
36 (85.7%) 
N=42 
Average number of 
medications used 4.7 ± 4.0  3.8 ± 2.66 
 
     
 
Type of Medicine 
Number of 
Women % of 111  
Number of 
Women % of 36 
Analgesic 40 (28.6)  2 (5.6) 
Anti-histamine 2 (1.4)  6 (16.7) 
Anti-microbial 10 (7.1)  3 (8.3) 
Asthma-related 21 (15)  6 (14.3) 
Bisphosphonate 8 (5.7)  0 (0) 
Contraceptives/HRT 29 (20.7)  5 (13.9) 
High Blood Pressure 39 (27.9)  15 (41.7) 
Multivitamin 39 (27.9)  10 (27.8) 
Other 38 (27.1)  20 (55.6) 
PPI/GERD 14 (10)  12 (33.3) 
Psychotropic 52 (37.1)  18 (50) 
Statin 29 (20.7)  2 (5.6) 
Steroids 18 (12.9)  4 (11.1) 
Supplement 51 (36.4)  15 (35.7) 
Thyroid hormone 23 (16.4)  7 (19.4) 
  
Age at Diagnosis 
      The reported age of diagnosis of TSC varied widely.  Some women were diagnosed 
prenatally, whereas one person
diagnosis was 15 years. Frequencies and stratification by independent and dependent status 
are provided in Figure 3.  Because the age of diagnosis was later than expected, we analyzed 
this variable in comparison to others. In general the more severely affected individuals 
received a diagnosis at a younger age.  This is further discussed in a later section. 
Family History 
      Of all the respondents, 73 (40.1%) indic
ranging from 34 women listing one affected family member to one respondent listing 
affected family members. The frequency of specific degrees of relation to the respondent is 
presented in Table 11. By this an
with no family history of TSC. This is higher than the expected 
expected to have a de novo
affected family members.  
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TSC History 
 was diagnosed as late as 62 years of age. The median age of 
Figure 3. Ages of TSC Diagnosis 
ated having another family member with TSC, 
alysis, our sample appears to contain 76.9% of individuals 
66 – 70% of individuals 
 mutation, but could also reflect less awareness or reporting of 
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Table 11. Family History Involvement in Women With TSC 
 
 
Independent 
Women 
Dependent 
Women 
   
 n (%) 
Women with no family history (de novo) 103 (73.6) N=140 
37 (88.1) 
N=42 
Women reporting family history 66 (47.1) N=140 
7 (17.5) 
N=42 
Average number of affected relatives 2.3 ± 1.7 1.75 ± 2.2 
 
Affected Relative Number of Women 
Mother 15 1 
Father 8 1 
Sister 16 1 
Brother 14 1 
Daughter 29 2 
Son 25 0 
Grandmother 3 1 
Grandfather 4 1 
Aunt 5 1 
Uncle 0 1 
Cousin – Female 7 1 
Cousin – Male 3 0 
Niece 8 0 
Other 6 0 
 
 Genetic Testing 
 
Table 12. Genetic Testing Results in Women With TSC 
Receiving Testing 
 
Mutation testing results 
N=93 n (%) 
   
TSC1 9 (9.7) 
TSC2 17 (18.3) 
No mutation identified 28 (30.1) 
Other 4 (4.3) 
Result Unknown 35 (37.6) 
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Ninety-three (51.1%) women indicated they did have genetic testing, while 69 (37.9%) said 
they did not; 13 (7.1%) did not know. Of those who did, 93 reported results presented in Table 
12.  Although over half of the women reported receiving genetic testing, over 37% of these did 
not know the results of their test, providing less information on the frequency of mutations in 
either TSC1 or TSC2.  
Seizure History  
      Seizure history included age of onset and frequency of seizures, as well as past and 
current medications used for seizure control and whether surgery was ever performed (Tables 
13-16). Overall, 114 (62.6%) women indicated having a history of seizures, with an average 
onset of 7.0 ± 10.8 years.  The majority (59.1%) of women reported a frequency of seizures as 
less than once a year. A lower frequency than would be expected in TSC reflects milder 
disease in independent women.  Thus the data is separated to show seizure history for 
dependent and independent women, the former of which have a higher prevalence of 
seizures. Fifteen women (13.2% of those with a seizure history) indicated having surgery for 
their seizures.  
 
Table 13. Seizure History in Women with TSC 
 
Seizure History Independent women Dependent women All women 
 
Number reporting seizures  
n (%) 
76 (54.3%) 
N=140 
38 (90.5%) 
N=42 
114 (62.6%) 
N=182 
Mean age of onset (years) 9.3 ± 11.8 2.5 ± 6.4 7.0 ± 10.8 
 Range in age of onset 
(years) 0 – 45  0 – 34 0 – 45 
 
Frequency 
 n (%) 
Independent Women 
N=69 
Dependent Women  
N=36 
All Women 
N=105 
At least once a day 5 (7.3) 6 (16.7) 11 (10.5) 
At least once a week, but not 
daily 6 (8.7) 9 (25) 15 (14.3) 
At least once a month, but not  
weekly 4 (5.8) 4 (11.10 8 (7.6) 
At least once every six 
months, but not every month 8 (11.6) 1 (2.8) 9 (8.6) 
Less than once a year 46 (66.7) 16 (44.4) 62 (59.1) 
Number reporting surgery 
for seizures 10 (13.2) 5 (13.2) 15 (13.2) 
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 In addition to asking about what current and previous seizure medications women 
used, we asked them to include the dosage, frequency, and an estimate of effectiveness on a 
scale of 1 to 3. Women used the scale to note how effective they believed the medication(s) to 
be; 1 “did not work well,” 2 “neutral,” “3 worked well.” Medication data is presented in Tables 
14 -16b. The most common seizure medication in use by independent women was Keppra, at 
an average dose of 1000 mg an average frequency of twice per day, taken for an average 
length of 4 years, and rated an average effectiveness of 3. For dependent women, the most 
frequently used current seizure medication was  Depakote, with an average dosage of 250 mg 
two times per day, an average length of 24 years, and average effectiveness of 3.  
 
Table 14. Medication History in Women with Seizure History 
 
 
Independent Women 
N=69 
Dependent Women 
N=38 
   
Reporting current medications 
n (%) 47 (68.1) 36 (94.7) 
Average number of medications 1.5 ± 0.9 1.7 ± 1.0 
 
Reporting previous medications 
n (%) 62 (89.9) 29 (76.3) 
Average number of medications 2.0 ± 1.6 3.1 ± 2.6 
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Table 15. Current Seizure Medications Reported by Women With TSC 
 
      
Independent 
women 
N=47 
Name 
Number 
of 
women 
Median 
dosage 
(mg) 
Median 
frequency 
Median  
years 
taken 
Median 
Effectiveness 
Depakote 5 250 2/day 24 3 
Diastat 1 - - - - 
Dilantin 2 300 1.5/day 27.5 2.5 
Felbatol 2 - 3/day 9 2.5 
Gabapentin 1 - - - - 
Keppra 14 1000 2/day 4 3 
Klonopin 2 0.75 2.5/day 6.5 - 
Lamictal 11 150 2/day 5 3 
Lorazepam 1 - - - - 
Neurontin 2 - - 5.5 2.5 
Phenobarbital 6 60 1/day 36 2.5 
Tegretol 11 300 2/day 18 3 
Topamax 6 150 2/day 6 3 
Trileptal 3 600 2/day 8 - 
Valium 1 - - - - 
Vimpat 1 - - - - 
VNS implant 1 - - - - 
Zonegran 2 - - - 2.5 
 
Dependent 
women 
N=36 
Banzel 2 - - - - 
Clobazam 1 - - - - 
Depakote 12 250 2/day 24 3 
Diastat 2 - - - - 
Dilantin 2 300 1.5/day 27.5 2.5 
Felbatol 2 - 3/day 9 2.5 
Keppra 4 1000 2/day 4 3 
Klonopin 3 0.75 2.5/day 6.5 - 
Lamictal 4 150 2/day 5 3 
Mysoline 1 - - - - 
Phenobarbital 4 60 1/day 36 2.5 
Sabril 3 - - - - 
Tegretol 10 300 2/day 18 3 
Topamax 3 150 2/day 6 3 
Trileptal 6 600 2/day 8 - 
Vimpat 2 - - - - 
Zonegran 2 - - - 2.5 
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Table 16a. Previous Seizure Medications Reported by Dependent Women With TSC 
 
     
Dependent 
Women 
N= 29 
Name Number of 
women  
Number years 
taken 
Average 
Effectiveness 
ACTH 2 1 2 
Ativan 1 - 0 
Clobazam 1 2 3 
Clonazepam 1 7 - 
Klonopin 3 0.12 1 
Depakote 10 1.75 1.5 
Dilantin 12 4.5 3 
Felbatol 3 9 3 
Gabitril 2 1.5 1 
Keppra 4 0.12 1 
Lamictal 7 1 1 
Lyrica 1 - - 
Mellaril 1 - - 
Mysoline 2 - 1 
Neurontin 1 0.5 1 
Phenobarbital 8 4 1.5 
Sabril 3 6 3 
Tegretol 13 8 1 
Topamax 3 1.1 1 
Tranxene 1 - 1 
Trileptal 2 - 1 
Unknown 3 - - 
Valium 2 5 0.5 
Zarontin 1 3 2 
Zonegran 3 4 1 
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Table 176b. Previous Seizure Medications Reported by Independent  Women With TSC 
 
     
Independent 
Women 
N= 62 
Name Number of 
women 
Number years 
taken 
Average 
Effectiveness 
ACTH 2 0.5 2 
Carbatrol 3 9 1.5 
Depakote 12 5 2 
Diamox 1 1 1 
Dilantin 33 6 2 
Felbamate 1 1 1 
Keppra 3 2.5 1 
Klonopin 1 5 1 
Lamictal 4 1 1 
Mogadon 1 -- 3 
Mysoline 2 1 1 
Neberil 1 -- 1 
Neurontin 8 1 1 
Phenobarbital 24 8 3 
Tegretol 21 5 2 
Topamax 3 2 1 
Trileptal 2 0.25 1 
Unknown 2 -- -- 
Vigabatrin 1 3 3 
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Clinical Manifestations 
      The last two sections of the TSC portion of the questionnaire focused on the presence of 
intellectual impairments, and specific clinical manifestations listed by affected organ. For each, 
women were asked to report a current /prior existence of diagnosis/manifestation, and the age 
at which they were diagnosed, where applicable.  
      By far, the most commonly reported neuropsychiatric diagnosis was depression, present in 
72 (39.6%) women (Table 17). The finding is considered in light of rates of depression in 
women, in individuals with genetic disease, and in individuals with other psychiatric 
disturbances and is discussed later. We further analyzed this by combining depression with 
other diagnoses (anxiety, OCD, bipolar disorder) into a sub-category of “mood disorders.” We 
found a prior or current diagnosis of these mood disorders in 65 (47.8%) independent women, 
and 22 (52.4%) dependent women, for total of 87 women (47.8%) in the sample. Further 
analysis between women with a history of a “mood disorder” and those women without is 
provided in Table 18. 
Other common diagnoses were learning disabilities, intellectual disability , and ADHD. Less 
common were OCD and  Autism, and dyslexia. As with seizures, it is expected that dependent 
women would be more severely affected by cognitive impairment; thus, the data for 
neuropsychiatric manifestations of TSC is shown separately for dependent and independent 
women.  
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Table 187. Diagnosis of Neuropsychiatric Disorder in Women with TSC 
 
n (%) 
Independent women 
 
Dependent women 
  
Disorder / 
Diagnosis 
Current / 
previous  
n (%) 
Age Diagnosed (years) Current / 
previous  
n (%) 
Age Diagnosed (years) 
Mean Range Mean Range 
Learning 
Disability 
35 (25.9) 
N=135 7.9 ± 5.3 2 – 20 
27 (64.3) 
N=42 5 ± 4.9 0 – 20 
ADHD 9 (6.7) N=134 12.9 ± 7.5 5 – 25 
8 (19.0) 
N=42 4.4 ± 3.5 1 – 10 
Autism 3 (2.2) N=134 3 ± 1.4 2 – 4 
9 (21.4) 
N=42 4 ± 5.4 1 – 16 
MR 4 (3.0) N=133 3.3 ± 1.5 2 – 5 
25 (59.5) 
N=42 3.2 ± 2.4 1 – 10 
Dyslexia 8 (5.9) N=135 12.7 ± 4.6 10 – 18 
2 (4.8) 
N=42 15 ± 7.1 10 – 20 
OCD 8 (6.0) N=134 21.4 ± 9.5 14 – 38 
6 (14.3) 
N=42 13 ± 4.2 10 – 16 
Depression 59 (42.8) N=138 27 ± 10.6 13 – 46 
13 (31.0) 
N=42 23.5 ± 9.6 10 – 35 
Bipolar 
Disorder 
5 (3.7) 
N=134 33.2 ± 10.9 18 – 47 
4 (9.5) 
N=42 23 ± 11.3 15 – 31 
Other 16 (28.6) N=56 26.4 ± 12 11 – 45 
9 (21.4) 
N=42 10.9 ± 8.5 1 – 25 
 
 
Table 19. Women with Mood Disorders: Statistically Significant Findings 
 
 n (%) (p<0.005) 
 
Finding Mood Disorder No Mood Disorder p value 
Shortness of Breath with Exertion  38 (43.7) 
n=95 
23 (24.1) 
n=87 0.022 
Night Sweats 9 (28,1) 
n=32 
3 (7.1) 
n=42 0.038 
Hot Flashes 8 (25,0) 
n=32 
1 (2.4) 
n=41 0.009 
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      To assess the severity of brain manifestations of TSC, we asked women to report a history 
of SEGA, and any associated treatment. Twenty-two (12.5%) women indicated being 
diagnosed with SEGA, while 44 (25.0%) reported they did not know. Of those who did, ten had 
treatment, all of which was reported to be surgery; one woman indicated both surgery and 
radiation.  
Clinical manifestations of TSC are presented in Table 19 and are separated into 
Dermatological, Renal, Pulmonary, and Cardiac categories. Specific manifestations are shown 
in Tables 20 – 23 for each organ system.    
 
Table 20. Overall Organ System Involvement in Women With TSC 
 
 
n (%) 
Organ System Independent women 
 
Dependent women 
  
Dermatological 133 (95.0) N=140 
42 (100.0) 
N=42 
Renal 80 (57.1) N=140 
30 (71.4) 
N=42 
Pulmonary 67 (47.9) N=140 
18 (42.9) 
N=42 
Cardiac 38 (27.1) N=140 
16 (38.1) 
N=42 
 
 
Table 21. Dermatological Involvement in Women With TSC 
 
 
n (%) 
Manifestation Independent women 
 
Dependent women 
  
Angiofibromas 115 (82.1) N=140 
39 (92.9) 
N=42 
Hypopigmented Macules 124 (88.6) N=140 
37 (88.1) 
N=42 
Finger / Toe Nail Tumors 84 (60.0) N=140 
25 (59.5) 
N=42 
 
 
42 
 
 
Table 22. Renal Involvement in Women With TSC 
 
 
n (%) 
Manifestation Independent women 
 
Dependent women 
  
Renal Cysts 63 (45.0) N=140 
27 (64.3) 
N=42 
Angiomyolipoma 63 (48.1) N=140 
22 (52.4) 
N=42 
Renal Cancer 3 (2.1) N=140 
3 (7.1) 
N=42 
 
 
 
Table 23. Pulmonary Involvement in Women With TSC 
 
 
n (%) 
Manifestation Independent women 
 
Dependent women 
  
Pulmonary Cyst 30 (21.4) N=140 
8 (19.1) 
N=42 
LAM 35 (25.0) N=140 
8 (19.1) 
N=42 
Shortness of Breath 
with Exertion 
47 (33.6) 
N=140 
14 (33.3) 
N=42 
 
 
Table 24. Cardiac Involvement in Women With TSC 
 
 
n (%) 
Manifestation Independent women 
 
Dependent women 
  
Rhabdomyomas 10 (7.1) N=140 
10 (23.8) 
N=42 
Irregular Heartbeat 33 (23.6) N= 
13 (31.0) 
N=42 
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POF  
    The reproductive histories of all women were looked at in detail. Women who had irregular 
cycles early in their lives that persisted were considered to have a different reproductive 
dysfunction.  However, women who had regular cycles most of their life but later changed to 
irregular cycles later in their reproductive lives, particularly after age 35 were considered to 
have possible POF as this is a common pattern in women have been documented with this 
diagnosis. This pattern was observed in 18 women; 16 independent women, and two 
dependent women. The group was further refined to exclude those women whose other 
information that was inconsistent or incomplete.  This resulted in a total of eight women who 
were deemed to have a “possible” diagnosis of POF. One of these women was dependent 
(discussed later), and the remaining seven were independent.  
Of note, four women out of the total 182 participants reported receiving a diagnosis of 
POF, but two were excluded due to contradictory and/or insufficient information. One woman 
indicated receiving a diagnosis of POF at age 45, which would not be clinically accurate.  She 
also reported a diagnosis of PCOS at age 42, a hysterectomy at age 32, and an oophorectomy 
at age 42. This history suggests she had other reproductive problems but is not consistent with 
a decline in ovarian reserve observed in POF. The second woman reported a diagnosis of 
POF at age 33. Her entire menstrual history was lacking with the exception of reported 
irregular periods without oral contraceptive use at age 40. Thus, we cannot assess her 
menstrual history for a progression from regular periods to irregular periods. Furthermore, this 
individual reported a miscarriage at age 40. The other two women reporting a diagnosis of 
POF are included in the group of seven women. One of these women reported a diagnosis of 
POF at age 39, and also reported a history of anorexia, a disease in which menstrual 
abnormalities are common. She did not, however, indicate an age of this diagnosis. The 
second women reported a diagnosis of POF at age 40. She indicated receiving radiation 
therapy at an unspecified location and age. This woman had no seizure history, no known 
history of SEGA, and therefore was unlikely to have received radiation to the head for TSC 
management. We cannot, however, exclude the possibility of pituitary failure due to disruption 
of the pituitary hypothalamic ovarian axis. In addition, her uterus and ovaries remained intact, 
making pelvic radiation – a more direct cause of POF - less likely.  
Analysis was performed on the seven independent with presumptive POF. Because of the 
global differences between independent and dependent women in this study, further analysis 
was performed in comparison to independent women only. A statistical comparison of all 
variables was made between these women and 110 independent women not determined to 
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have possible POF over the age of 30. in an effort to use a population both similar to the 
seven women being studied, and to a typical presentation of POF itself. Information for the one 
dependent woman with possible POF is summarized in Appendix B. 
      The data for women with possible POF is presented in Tables 24 - 44. There were four 
statistically significant findings in the comparison between women with possible POF and 
independent women over the age of 30 without possible POF. These include: Lower frequency 
of hypopigmented macules in women with possible POF (Table 41); A higher frequency of 
reported high blood pressure in women with possible POF (Table 28); Report of blood tests 
revealing a menopausal state in women with possible POF as compared to independent 
women without possible POF between the ages of 30 and 40 (Table 29); A higher frequency of 
reported shortness of breath upon exertion in women with possible POF (Table 45).  
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Table 25. Demographic Information: Independent Women With Possible POF and 
Independent Women Without Possible POF over the age of 30   
 
 
Possible 
POF Non-POF    
Possible 
POF Non-POF  
 
n (% of 7) n (% of 110)   n (% of 7) n (% of 110) 
 
Age 
 Marital Status 
Median: 44 years 35 years  Single 1 (14.3)  20 (18.2) 
Range: 18 – 77 years 18 – 68 years  Married 4 (57.1) 71 (64.6) 
    
Divorced 1 (14.3) 15 (13.6) 
    
Widowed 1 (14.3) 4 (3.6) 
   
Employment Status 
 Annual Household Income 
Unemployed 1 (14.3) 23 (20.9)  < $10,000 0  6 (5.5) 
Part-time 0 13 (11.8)  $10,000 – 24,000 1 (14.3) 10 (9.1) 
Full-time 2 (28.6) 50 (45.5)  $25,000 – 49,000 0 24 (21.8) 
Student 0 1 (0.9)  $50,000 -74,999 0 13 (11.8) 
Disabled 1 (14.3) 9 (8.2)  $75,000-99,999 3 (42.9) 19 (17.3) 
Retired 3 (42.9) 7 (6.4)  > $100,000 0 11 (10.0) 
Other 0 7 (6.4)  Decline / blank 3 27 (24.5) 
 
Household Status 
 Highest Education Level 
Alone 1 (14.3) 20 (18.2)  Under 12th grade 0 2 (1.9) 
With family 5 (71.4) 63 (57.3)  Completed 12
th
 
grade 4 (57.1) 20 (18.2) 
With S/O 1 (14.3) 27 (24.6)  Some college 1 (14.3) 36 (32.7) 
Assisted 
living 0 0  
Bachelor / Master 
degree 2 (28.6) 52 (47.3) 
 
Ethnicity 
 
   
Caucasian 6 (85.7) 102 (92.7) 
 
   
African-
American 1 (14.3) 2 (1.8)     
Hispanic 0 1 (0.9) 
 
   
Asian 0   1 (0.9) 
 
   
Other 0  4 (3.6) 
 
   
 
      The majority of the seven women with possible POF were Caucasian, married, working 
full-time or retired, and had completed high school and/or some college (Table 24).  Though 
they all displayed menstrual irregularity of consistently regular cycles to consistently irregular 
cycles, the average age of menarche (12.7 years) was comparable to both the other women 
 sampled and the general population (Table 25 and Figure 4). This suggests intact ovarian 
function at the start of puberty. Rates of pregnancy were also similar to that of the 
population, and women on average had 1.
21.8 years. One of the seven women reported miscarriage 
birth, and 0 reported a history of voluntary termination (Tables 26 and 27).
 
Menstrual category
 
Always regular
Always irregular
Regular to irregular
Alternating regularity
Uninformative
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6 children, with an average age of first pregnancy of 
at age 31, one reported preterm 
 
 
 
Table 26. Menstrual History 
No POF  
N=110  
Possible POF
N=7 
 n (%)  n (%) 
 
 59 (53.6)  0 
 15 (13.6)  0 
 6 (5.5)  7 (100)
 12 (10.9)  0 
 18 (16.4)  0 
Figure 4. Age of Menarche 
10 11 12 13 14 15 16 17
Age (years)
Possible POF 
Mean: 12.7 years 
No POF 
Mean: 12.4  years 
entire study 
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1.5
1.6
47 
 
 
Table 27. Pregnancy 
 
Non POF  Possible POF 
  
Women pregnant at any time 75 (68.2 %) N=110  
5 (71.4%) 
N=7 
Average number of live births 1.8 ± 1.6  1.6 ± 0.5 
Average age at first birth 25.6 ± 5.7  21.8 ± 2.9 
Number of women who had a preterm 
birth 
5 (8.4%) 
N=68  
1 (20%) 
N=5 
Women who had a voluntary termination 15 (20.0%) N=75  0 
 
 
Table 28. Miscarriage History 
   
 Non POF Possible POF 
Women who had a miscarriage 32 (43.2%) 
N=74 
1 (20.0%) 
N=5 
Average age of miscarriage 28.6 ± 6.2 31 
Average number of miscarriages 1.7 ± 1.1 1 
 
     The most commonly reported current or previous reproductive symptoms were hot flashes, 
night sweats, high blood pressure, and weight gain, each present in over half of women with 
possible POF (Table 28). Two women indicated receiving a blood test indicating a menopausal 
state (Table 29). Three had a hysterectomy, and two reported oophorectomy. These occurred 
at an average age of 43.5 and 44 years, respectively (Table 30). Of the reproductive disorders, 
diagnoses of infertility, amenorrhea, and autoimmune disease were reported in three women 
with possible POF; frequencies of all reproductive disorders are provided in Table 31. There 
were, on average, 4 medications taken by women with possible POF. Categories and 
frequencies of medications are shown in Table 32.  
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Table 29. Reproductive Symptoms  
 
Non POF  
Under the Age of 40 
 
POF 
Symptom 
Current or 
previous 
n (%) 
Average 
duration 
(years) 
Current or 
previous  
n (%) 
Average 
duration 
(years) 
 
Hot Flashes 4 (15.4) N=26 4.5 ± 4.8   
5 (83.3) 
N=6 Unknown 
Night Sweats 8 (30.8) N=26 1.3 ± 0.5  
5 (83.3) 
N=6 
Unknown 
Body Hair 6 (23.1) N=26 12.5 ± 10.7  
0 
N=6 Unknown 
High Blood Pressure* 8 (30.8) N=26 3 ± 0  
5 (83.3) 
N=6 Unknown 
Milky breast discharge 
excluding breastfeeding 
6 (23.1) 
N=26 1.1 ±1.3  
1 (16.7) 
N=6 Unknown 
Weight gain over 25 
pounds, excluding 
pregnancy 
11 (42.3) 
N=26 N/A  
4 (66.7) 
N=6 N/A 
* p=0.027 
 
 
Table 30. Reproductive Blood Tests  
 
 
Non POF  
Under the Age of 40 
 
Possible POF 
Blood Test Indicating: n (%) n (%) 
Menopausal State* 0  N=12 
2 (28.6) 
N=7 
Thyroid Disease 3 (25) N=12 
1 (14.3) 
N=7 
Elevated Testosterone 
Levels 
1 (8.3) 
N=12 
0 
N=7 
*p = 0.009 
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Table 31. Surgical History in Independent Women with TSC 
 
 Non POF 
 
Possible POF 
Surgery N (%) Average Age N (%) 
Average 
Age 
Hysterectomy 31 (28.7) N=108 35.4 ± 9.8 
3 (57.1) 
N=7 43.5 ± 7.8 
Oophorectomy 17 (16.2) N=105 41.2 ± 7.7 
2 (28.6) 
N=7 44 ± 7.1 
Radiation therapy 2 (1.9) N=106 Unknown 
1 (14.3) 
N=7 *  Unknown 
Chemotherapy 1 (1.0) N=106 45 
0 
N=7 N/A 
*site of radiation unknown 
 
 
Table 32. Reproductive Diagnoses 
 Non POF 
 
Possible POF 
Diagnosis N (%) Average Age Diagnosed N (%) 
Average Age 
Diagnosed 
  
POF 2* (1.9) N=108 39 ± 8.5  
2 (33.3) 
N=6 39.5 ± 0.71 
PCOS 10 (9.4) N=107 34.7 ± 14.2   0 N/A 
Amenorrhea 9 (8.4) N=107 30.6 ± 11.5  
1 (16.7) 
N=6 Unknown 
Infertility 12 (11.1) N=108 31.2 ± 6.3  
1 (16.7) 
N=6 28 
Anorexia 4 (3.7) N=108 20.3 ± 1.5  
1 
(16.7) 
N=6 
N/A 
Addison disease 1 (0.9) N=107 41  
0 
 
N/A 
Autoimmune Disease 13 (12.2) N=107 36.6 ± 15.0   
0 
 
Unknown 
* Excluded from possible POF group due to inconsistent/contradictory information 
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Table 33. Current Medications (Non-seizure) in Independent Women with TSC 
Type of Medicine Non-POF Possible POF 
Number of women reporting medication 87 (79.8%) 4 (57.1%) 
Average number of medications used 5.2 ± 4.2 4 
 Analgesic 36 1 
Anti-histamine 18 0 
Anti-microbial 8 2 
Asthma-related 21 0 
Bisphosphonate 8 0 
Contraceptives/HRT 20 1 
High Blood Pressure 26 1 
Multivitamin 35 0 
Other 40 4 
PPI/GERD 12 2 
Psychotropic 43 2 
Statin 25 2 
Steroids 14 1 
Supplement 104 0 
Thyroid hormone 21 0 
   
    Overall, our data for the entire study population indicated a later age of TSC diagnosis, a 
higher prevalence of mood disorders, and a less severe course of TSC disease. The seven 
independent women with possible POF did not appear significantly different in regard to their 
clinical severity. The average age of TSC diagnosis was 23.7 years (Figure 4). A family history 
of TSC was reported by six of the women, indicating a lower rate of apparent de novo disease. 
Frequencies of affected relatives with respect to the survey participants are shown in Table 33.  
Genetic testing results are shown in Table 34. Three women with possible POF reported 
receiving testing, but two did not know the result. Unknown mutation testing results was also 
seen in the entire sample population, providing little data to utilize genotype in hypothesizing a 
correlation with women’s’ reproductive history.  
 
 
 
 
 
 
  
Table 34. Family History 
 
 
Women reporting family history
Average number of affected relatives
Mother
Father
Sister
Brother
Daughter
Son
Grandmother
Grandfather
Aunt
Uncle
Cousin –
Cousin 
Niece
Nephew
Other
Women with unknown family history
Women with no family history (
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Figure 5. Ages of TSC Diagnosis 
 
Reported in Women with TSC
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n (%) 
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Table 35. Genetic Testing Results in Independent Women with TSC 
 
 n (%) 
Women reporting genetic 
Testing 
Non POF Possible POF 
61 (55.5) 
N=110 
3 (42.9) 
N=7 
   
TSC1 6 (9.8) 0 
TSC2 10 (16.4) 1 (33.3) 
No mutation identified 20 (32.8) 0 
Other 2 (3.3) 0 
Don’t Know result 23 (37.7) 2 (66.7) 
 
      Data on seizure history, age of onset, and frequency is shown in Table 35. Four of the 
seven women reported a history of seizures, with a mean age of onset of two and a half years. 
All of these women reported a seizure frequency of less than once a year. One women 
currently uses seizure medication, and the four mentioned above provided  information on 
previous seizure medication use. Data on seizure medication are presented in Tables 36-38. 
The possible relationship between seizure history, anti-epileptic drug use, and menstrual 
irregularities is provided in the discussion section.  
 
Table 36. Seizure History in Independent Women with TSC 
Seizure History Non POF Possible POF 
Number reporting seizures 55 (50.0%) N=110 
4 (57.1%) 
N=110 
Mean age of onset (years) 11.6 ± 12.7 2.5 ± 2.4 
Range in age of onset (years) 0.3 – 45 0 – 5 
 
Frequency n (%) N=49 N=4 
At least once a day 4 (8.2) 0 
At least once a week, but not 
daily 4 (8.2) 0 
At least once a month, but not  
weekly 3 (6.1) 0 
At least once every six months, 
but not every month 8 (16.3) 0 
Less than once a year 30 (61.2) 4 (100) 
Number reporting surgery for 
seizures 5 (9.1) 0 
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      Table 38. Seizure Medication History in Independent Women with TSC 
 
Non POF Possible POF 
N 
 (% of women with seizure history) 
   
Reporting current seizure medications 30 (27.3) N=110 
1 (25) 
N=4 
Average number of medications 1.6 ± 0.9 1 
 
Reporting previous seizure medications 41 (37.3) 4 (100) 
Average number of medications 1.8 ± 1.3 1.4 ± 0.55 
 
 
 
 
 
Table 37. Current Seizure Medications in Independent Women with TSC 
 
       
 Name 
Number 
of 
women 
Median 
dosage 
(mg) 
Median 
frequency 
(X / day) 
Median  
years 
taken 
Median 
Effectiveness 
Non POF  
N=30 
Depakote 4 375 3 19 2.5 
Dilantin 2 300 1.5 27.5 2.5 
Felbatol 1 600 4 15 2 
Gabapentin 1 600 2 4 2 
Keppra 9 750 2 3.5 3 
Klonopin 2 .75 2.5 6.5 3 
Lamictal 7 300 2 4 3 
Lorazepam 1 1 1 13 1 
Phenobarbital 6 60 1 36 2.5 
Tegretol 8 350 2 20 3 
Topamax 4 175 2 2 2 
Trileptal 1 1800 1 9 3 
Valium 1 5 1 6 3 
Zonegran 2 75 2 4 2 
 
Possible POF  
N=1 Neurontin 1 300  3 10 3 
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Table 39. Previous Seizure Medications in Independent Women with TSC 
 
 
 Name Number of 
women  
Number years 
taken 
Average 
Effectiveness 
Non POF  
N= 40 
ACTH 1 1 3 
Carbimazole 1 6 2 
Cortizone 1 1 3 
Depakote 7 1 1.5 
Dilantin 24 3.75 2.5 
Keppra 1 2 1 
Lamictal 1 1 1 
Mogadon 1 - 3 
Mysoline 1 0.5 1 
Neberil 1 - 1 
Neurontin 6 1 1 
Phenobarbital 15 6.5 3 
Tegretol 11 5.5 2 
Topamax 1 - - 
Trileptal 1 - - 
Unknown 2 - - 
 
Possible 
POF 
N=4 
Dilantin 2 14 2 
Phenobarbital 1 2 2 
Tegretol 1 - 1 
   
       Depression was the most common psychiatric manifestations of TSC in these seven 
women, present in five women (Table 39), with an average duration of 27 years. This adds to 
the high numbers of depression observed in the entire study sample.  
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Table 40. Diagnosis of Neuropsychiatric Disorder in Independent Women with TSC 
  
Non POF Independent Women 
 
Possible POF Independent Women 
  
Disorder 
Current or 
previous 
diagnosis 
N (%) 
Average age 
diagnosed 
(years) 
Current or 
previous 
diagnosis 
N (%) 
Average age 
diagnosed 
(years) 
Learning 
Disability 
25 (23.4) 
N=107 8.4 ± 4.6 
1 (16.7) 
N=6 18 
ADHD 7 (6.6) N=106 15.6 ± 7.2 0 - 
Autism 0 - 0 - 
MR 0 - 0 - 
Dyslexia 6 (5.6) N=107 14 ± 5.7 
1 (16.7) 
N=6 Unknown 
OCD 6 (5.7) N=106 23.3 ± 9.9 0 - 
Depression 49 (45.0) N=109 28.2 ± 10.8 
5 (71.4) 
N=7 27 
Bipolar 
Disorder 
5 (4.7) 
N=106 33.2 ± 10.9 0 - 
Other 14 (28.6) N=49 28.7 ± 11.9 
1 (33.3) 
N=3 14 
 
   Lastly, the manifestations of specific organ systems affected by TSC are presented in Tables 
40 through 44. Aside from the differences in the aforementioned dermatological manifestations 
a comparable number of women indicated the presence of renal, pulmonary, and cardiac 
issues in both groups.  
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Table 41. Overall Organ System Involvement in Independent Women 
with TSC 
   
n (%) 
Organ System Non POF N=110 
 
Possible POF 
N=7 
  
Dermatological 106 (96.4) 5 (71.4) 
Renal 65 (59.1) 4 (57.1) 
Pulmonary 58 (52.7) 4 (57.1) 
Cardiac 28 (25.5) 4 (57.1) 
 
 
Table 42. Dermatological Involvement in Independent Women with TSC 
 
n (%) 
Manifestation Non POF N=110 
 
Possible POF 
N=7 
  
Angiofibromas 91 (82.7) 4 (57.1) 
Hypopigmented Macules* 97 (88.2) 5 (74.1) 
Fingernail / Toenail 
Tumors 68 (61.8) 3 (42.9) 
* This finding was statistically significant, with a p value of 0.021 
 
 
Table 43. Renal Involvement in Independent Women with TSC 
 
n (%) 
Manifestation Non-POF N=110 
 
Possible POF 
N=7 
  
Renal Cysts 51 (46.4) 4 (57.1) 
Angiomyolipoma 52 (47.7) 2 (28.6) 
Renal Cancer 3 (2.7) 0 
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Table 44. Pulmonary Involvement in Independent Women with TSC 
 
n (%) 
Manifestation Non-POF N=110 
 
Possible POF 
N=7 
  
Pulmonary Cyst 26 (23.6) 2 (28.6) 
LAM 29 (26.4) 3 (42.9) 
Shortness of Breath with Exertion* 41 (37.3) 5 (71.3) 
* p  = 0.024 
 
 
Table 45. Cardiac Involvement in Independent Women with TSC 
 
n (%) 
Manifestation Non-POF N=110 
 
Possible POF 
N=7 
  
Rhabdomyomas 4 (3.6) 1 (14.3) 
Irregular Heartbeat 27 (24.5) 4 (57.1) 
 
 
Table 46. Women with Possible POF: Statistically Significant Findings 
 
 n (%) (p<0.005) 
 
Finding Possible POF Non-POF p value 
Shortness of Breath with Exertion  5 (71.3) N=7 
41 (37.3) 
N=110 0.024 
High Blood Pressure  
 
5 (83.3) 
N=6 * 
3 (25) 
N=12 0.024 
Blood Test Indicating Menopausal State 0 * 2 (28.6) N=7 0.009 
Hypopigmented Macules 5 (74.1) N=110 
97 (88.2) 
N=7 0.021 
* Comparison was limited to independent, non-POF women between the ages of 30 and 40 
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     Overall, our data for women with possible POF is based on clinical refinement of self-
reported menstrual histories and trends. The limited sample size makes a comparison to 
women whose histories were not suggestive of POF difficult. However, the small differences 
noted and other observations in the overall population do warrant further discussion.  
Discussion 
 
       This study was designed to estimate the prevalence of premature ovarian failure in a         
sample of women affected with TSC.  It is the first study to highlight significant menstrual 
dysfunction in women with TSC. The hypothesis was based on evidence from conditional 
knock-out mice models that indicated the importance of the TSC genes and mTORC 
regulation in murine ovarian function. The aim of the study was to determine what, if any, 
association may exist between the development of POF and TSC in women. Questionnaires 
were sent to 1000 adult female members of the Tuberous Sclerosis Alliance, a national 
support group, providing self-reported data on demographics, reproductive history, and TSC 
manifestations. A total of 182 qualifying surveys were informative and used in the analysis, 
and 18 surveys were excluded due to insufficient information or underage respondents. 
Demographic analysis demonstrated a high socio-economic status for this group of 182 
women.  TSC clinical data suggested milder disease than typically observed in TSC patients. 
As variable expressivity is a well-established feature of TSC, we did not anticipate that milder 
disease would underestimate the presence of reproductive issues in these women. In fact, 
given this caveat, our study would be predicted to underestimate reproductive problems in the 
overall TSC female population.   
POF   
Our data suggest that there is an increase in the prevalence of POF in women with TSC 
compared to the general population. Analysis of 182 women categorized 9 with “possible POF” 
(4.95%). Two of these women reported receiving a diagnosis of POF. The selection of women 
from which to consider the possibility of POF was created through application of stringent 
reproductive and menstrual criteria. Since the diagnosis of POF involves the cessation of 
menses before the age of 40, self-reported data of menstrual history for time frames between 
18 and 40 were used as an initial filter to categorize women. The natural history of POF 
typically involves regular menses, followed by irregular cycles, before the complete cessation 
of menses. Therefore, women considered for a categorization of “possible POF” were 
identified by menstrual trends indicating consistently regular cyclicity progressing to 
consistently irregular cyclicity as previously defined in the Methods. Our refinement resulted in 
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a sample of 18 women. Of these, nine were excluded upon further analysis of clinical features, 
as their histories were consistent with other reproductive disorders, such as PCOS. The 
remaining eight women included seven independent respondents and one dependent 
respondent. Independent women were those that completed the questionnaire themselves, 
whereas dependent women were those for whom a questionnaire was completed by a 
caretaker, suggesting more severe TSC manifestation or cognitive disability. Because our 
initial comparisons of independent and dependent women in the entire sample of women 
revealed differences between these groups, the dependent woman was excluded from further 
analysis of the group with possible POF. Furthermore, it is less likely that women would 
present with POF in their 20s, so comparison between the seven independent women with 
possible POF was limited to independent women over the age of 30 years. Choosing this age 
constraint allowed for a more direct comparison of groups. 
Few studies have empirically assessed the prevalence of POF in the general population. 
The literature primarily quotes an estimate of 1% that comes from a longitudinal study from 
1983 [Coulam]. Previously, estimates of POF came from cohort studies analyzing specific and 
narrow age ranges. Coulam, et al. followed a cohort of 1858 women and found an incidence of 
0.9%. They also reported that the risk to develop POF increases from 0.1% at age 30 to 1% by 
40 years of age; a ten-fold increase over a ten year period. Thus, our finding of possible POF 
in nine (4%) of women studied is a significant finding, particularly as only two of these women 
reported receiving a diagnosis of POF. As discussed earlier, there is often a delay in the 
diagnosis of POF, especially for women who are not struggling with conception. Other causes 
for delayed diagnosis are varied symptomatology and other etiologies for isolated menstrual 
irregularity. In women with a genetic condition that affects multiple organ systems, attention to 
additional symptoms or medical problems may be misconstrued as related to TSC or 
overlooked entirely. No studies have previously attempted to assess if there is an association 
between TSC and menstrual irregularities such as POF.  
Because we were not able to obtain medical data from women, we do not know if the 
women with possible POF would have had elevations in FSH levels,  necessary for a clinical 
diagnosis. Thus our results fit with a broader possibility of premature ovarian insufficiency, or 
POI,  as was introduced earlier. This term encompasses declining ovarian reserve, which we 
observed in analyzing women’s menstrual trends. The distinction is an important one, as we 
lack clinical data to confirm diagnoses in these women, and the accuracy of “insufficiency” 
better reflects a condition marked by reversibility and many unknowns. 
60 
 
Analysis of women with possible POF was performed by comparing all variables for 
significant associations. There was no statistically significant association between women with 
or without possible POF with respect to age, demographic information, BMI, medication use, 
seizure history, age at menarche, number of pregnancies or miscarriages, genetic testing 
results, neuropsychiatric diagnoses, or TSC-related manifestations in cortical, pulmonary, 
cardiac, or renal systems. The only statistically significant findings among these women in 
comparison to the independent women without possible POF were related to reproductive 
symptoms, report of receiving a blood testing indicating a menopausal state, and the presence 
of facial angiofibromas, which were present in a smaller percentage (57.1%) of women with 
possible POF compared to those without POF (82.6%). These findings could represent a true 
association, or may be due to limitations of a small sample size or statistical chance. High 
blood pressure and shortness of breath are both prevalent in the general population, 
particularly in women at older ages. It may be expected that women experiencing menstrual 
irregularity would have a blood test indicating a menopausal state, which may not necessarily 
lead to a diagnosis of POF. As for the dermatological finding, additional manifestations of 
these women were consistent with the rest of the sample, making it more likely that these 
women were at increased risk for POF due to specific manifestations of TSC. The absence of 
significant differences between women  is consistent with the theoretical possibility that TSC 
can manifest in any organ system, and does not suggest an increased likelihood in women 
with more severe TSC disease from our specific sample. There was little data on genetic 
testing results to uncover genotype/phenotype correlations, and thus further exploration of 
reproductive issues in women with TSC would be useful in conjunction with molecular 
information. It is noteworthy that there were no differences between the POF in mice with a 
Tsc1 specific ovarian deletion compared to Tsc2 [Adhikari, 2010].  Other reproductive 
problems revealed in these women suggest implications for ovarian function from mutations in 
the TSC genes and warrant further study.  
Additional data about reproductive history were considered in the eight women with 
possible POF. Two women reported receiving radiation therapy, though we do not know the 
ages when the treatment occurred. One woman indicated the therapy was for SEGA 
treatment, while the other did not indicate a location. Radiation to the brain could disrupt the 
hypothalamic-pituitary-ovarian axis, indirectly disrupting ovarian function. Alternatively, it is 
known that pelvic irradiation can lead to POF, and shows an age and dose-dependent effect 
[Nippita]. From the information given we cannot exclude either possibility for these 
respondents, nor can we discern the likely effects of radiation on menstrual function without 
knowing the ages when therapy occurred. Next, one woman did indicate a diagnosis of 
61 
 
anorexia from the list of reproductive disorders. Anorexia  is a known contributor to menstrual 
irregularity, but the respondent did not specify an age at which the diagnosis of anorexia 
occurred, negating a clear interpretation of any potential effects on the menstrual history. 
Anorexia is more common in adolescence (ages 14-18), though recent evidence suggests it 
may also be common among older women [American Psychiatric Association; Parker-Pope]. 
The study participant was 57 at the time the survey was completed, and her menstrual 
irregularity began at age 37, though she did report use of oral contraceptives between the 
ages of 21 and 30. She has symptoms of high blood pressure, takes Metformin, and has a 
BMI over 32; thus it is unlikely her diagnosis of anorexia was recent given her history. Without 
further information, we cannot depend on the respondent’s history of anorexia alone as a route 
to menstrual irregularity. Report of additional reproductive problems varied across the 8 
women but did include reproductive symptoms of night sweats and hot flashes, infertility, 
and/or blood tests indicating a menopausal state. These would be consistent with a diagnosis 
of POF, as women with POF experience perimenopausal symptoms at an earlier age than is 
expected, and may be evaluated for reproductive dysfunction by infertility specialists or as they 
near the age of menopause. Our reproductive and menstrual data indicate the criteria used for 
considering women for POF are reliable, as most women with a consistent menstrual history 
lacked contradictory information and instead contributed additional characteristics pointing to a 
possibility of POF 
Lastly, we analyzed if there were associations between POF and a history of seizures, as 
well as current /previous seizure medications. Reproductive endocrine disorders and infertility 
are more common among women with epilepsy than the general population, observations that 
have been attributed to both epilepsy itself and the use of anti-epileptic drugs (AED)s. for 
treatment [Isojarvi]. Epilepsy may directly affect reproductive function through disrupted 
regulation of hypothalamic hormone release [Pimentel]. Additionally, many women with 
epilepsy have catamenial seizures, presenting during menses and menopause when the 
levels of steroid ovarian hormones change. The risk from AEDs is thought to originate from 
their pharmacological induction of liver enzymes that gradually decrease the bioactivity of 
ovarian hormones and androgens [Isojarvi]. Additionally, valproic acid has been reported to 
have a possible effect on fertility, while limited data exists for the effects of gabapentin and 
lamotrigine on reproductive function or fertility [Kaplan 2004].  
We assessed if the use of AED or seizure history could be a possible explanation for the 
etiology of possible POF in the sample of eight women. Two women reported use of current 
seizure medications. These were lamotrigine, topirimate, and gabapentin. The two former 
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medications were reported as current from one woman and were used for 16 years. The time 
frame when the study participant  reported an onset of irregularity is that immediately following 
the start of her medication use. She also had the highest frequency of seizures of the women 
with possible POF, occurring no greater than twice per month. Current use of gabapentin was 
reported by one woman, for ten year duration. She reported the onset of menstrual irregularity 
at age 38, approximately three years following the first use of this medication; she also 
reported her last seizure occurred at age 28. Previous seizure medication use was reported for 
five of the eight women with possible POF, and included phenytoin, valproic acid, 
phenobarbital, and carbamazepine. None of these medications were used more than 14 years, 
and the majority were ceased at least ten years prior to the onset of menstrual irregularity. We 
cannot completely exclude the possibility that these medications had an effect on the 
menstrual function of these women. However, there were also three women in the group with 
possible POF that reported no history of seizures, and three women who reported an early 
childhood onset of seizures and cessation of AED use several years prior to the onset of 
menstrual irregularity. Our data suggest that neither seizures nor seizure medications alone 
would be sufficient to account for the onset of POF in all women.  
There were nine women who were excluded upon further refinement of the group showing 
a history of menstrual regularity to irregularity. Clinical guidance from a reproductive 
endocrinologist suggested other reproductive disorders in these women, including PCOS (one 
subject reported a diagnosis of PCOS). We also found that overall, 31% of women with TSC 
experienced some sort of menstrual irregularity. A number of women in the entire sample 
reported a diagnosis of amenorrhea and infertility, mostly diagnosed by gynecologists and 
infertility specialists. But a greater number with various forms of menstrual irregularities did not 
report a diagnosis of any reproductive disorder. Furthermore, only a handful of these women 
indicated having a blood test showing a menopausal state, thyroid disease, or elevated 
testosterone levels. Overall our data suggest there is a lack of awareness of reproductive 
issues in women with TSC. In light of missing data and an absence of medical chart review, it 
is likely we have underestimated reproductive dysfunction in general and POF in particular for 
the TSC population studied. Thus, thorough evaluation and attention to menstrual history, as 
well as proper hormonal assessment of women with TSC is indicated, and further research will 
aid in determining specific risk factors and characteristics of this issue.  
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Additional Findings from the entire sample of women 
Reproductive History 
Although not originally intended as part of the study design, several other findings are 
notable. The age of menarche in our sample was consistent with the national average (12.3 
years), and points to intact menstrual functioning at the onset of menses [Anderson]. In 
general, it is not uncommon for young women to display pubertal irregularities of abnormal 
uterine bleeding during the initial 19 months of menstruation, typically reported with 
anovulatory cycles due to an immature hypothalamic-pituitary-ovarian axis [Lemarchand-
beraud]. The duration of time that it takes to establish regular ovulatory cycles may to be 
related to age at the time of menarche, and in most girls who begin menses between the ages 
of 12 and 13, 50% of cycles are ovulatory by three years [Apter]. As the women in our survey 
had an average age of menarche of 12, with a 75th percentile of 13, it would be expected that 
any pubertal irregularities would normalize by the age at which data collection began, 16 
years. Thus, irregularities in the first time frame surveyed (16-20 years) were not considered to 
be due to pubertal irregularity and were instead counted as irregular.  Initial normal 
menstruation is consistent with a gradual progression to later development of POF.  
Another metric for reproductive health is a history of pregnancy and miscarriage. We 
found that 41.8% of women who reported ever being pregnant experienced a miscarriage, 
higher than observed in the general population. The approximate distribution of miscarriage 
rate estimates in the general population varies with maternal age; below 35 years, it is 
estimated that women have a 15% risk to experience miscarriage; between 35-39 years, a 20-
25% risk; between 40-42 years, 35% risk, and over 42 years, a 50% risk [American Pregnancy 
Association]. We also observed that the average age when these miscarriages took place in 
our sample (28.5 years) was younger than the above ranges. A higher miscarriage rate at 
younger ages may point to separate or additive effects related distinctly to TSC and not seen 
in the general population. Lastly, 50% of the women who experienced miscarriage had a 
menstrual history of always regular cycles, suggesting that menstrual irregularity alone is not a 
sufficient predictor of miscarriage risk in women with TSC. Furthermore, as dependent women 
generally became pregnant less often, we have limited data to assess whether severity of TSC 
symptoms might play any role in the risk for miscarriage. Of 33 women reporting miscarriage, 
17 (42.5%) also reported a history of seizures, while 16 (45.7%) reported no history of 
seizures. Studies of pregnancy women with epilepsy have not observed significantly elevated 
rates of fetal loss, though it does occur. Similar to the effects of epilepsy on menstrual 
functioning previously discussed, it is difficult to differentiate between risks from seizures and 
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AED use [Kaplan 2007]. A prospective study of pregnant women with epilepsy from 1994 
observed 21% rate of fetal loss in a group of 119 women receiving AEDs, and a 12.2% rate of 
fetal loss in 106 women not receiving medication [Steegers-Theunissen]. The elevated rates of 
miscarriage at young ages suggest a distinct finding for women with TSC, for whom there is 
little information on predictive factors or breadth of this issue.  
Of the reproductive diagnoses reported and menstrual histories consistent with specific 
reproductive dysfunction, PCOS was self-reported in 11 (6.04%) of the 182 women. We also 
identified four women whose information was more consistent with that seen in PCOS from 
our initial group of 18 women with a menstrual history of regular. PCOS is among the most 
common menstrual irregularities in women today, with an estimated prevalence between 6 and 
8% [Knochenhauer]. Risk factors and/or associations include infertility, insulin resistance, 
diabetes mellitus, and family history [Allen; Hartz; Conn; Legro]. Of note, studies also indicate 
the use of valproic acid to be associated with PCOS, and the drug may increase androgen 
biosynthesis in theca cells [Bilo; Nelson-DeGrave]. Many healthcare providers monitor the 
length of the menstrual cycles in women with epilepsy after commencement of treatment with 
valproate [Isojarvi; Kaplan 2004]. A total of 14 women reported current use of valproate, and of 
these, one indicated a diagnosis of PCOS, at age 45. Twenty-one women reported previous 
use of valproate, one of whom indicated a diagnosis of PCOS at age 48.  
Another common cause of menstrual irregularity, particularly oligomenorrhea and 
menorrhagia, is hypothyroidism. A study reported such irregularities in approximately 23.4% of 
women with hypothyroidism [Krassas]. The prevalence of overt hypothyroidism may vary from 
0.1 to 2 percent in the population, while subclinical hypothyroidism is higher, ranging from four 
to ten percent of adults, and is 5-8 times more common in women [Tunbridge; Kajantie]. We 
observed 43 women (24.0%) reporting a blood tests indicating thyroid disease. Of the group of 
18 women progressing from regular to irregular periods, four reported receiving a blood test 
indicating thyroid disease, and one of these women is included in our group of possible POF. 
Of the women with alternating cycles, six indicated thyroid disease, one of whom specified a 
diagnosis of Hashimoto thyroiditis. Lastly, six of the 24 women whose menstrual history was 
consistently irregular indicated thyroid abnormalities. Though we do not know the specific type 
of thyroid disease we did observe menstrual abnormalities in approximately half of the 43 
women with self-reported blood tests indicating thyroid disease, higher than that reported in 
hypothyroidism.  
Menstrual and reproductive problems specific to the TSC population remain unreported in 
the general population and thus all of these novel findings are relevant to TSC. The true 
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menstrual function of the women whose menstrual history was deemed uninformative is 
unknown, whether obscured by the use of oral contraceptives or intrauterine contraceptive 
device, terminated with reproductive surgery, or simply missing from the analysis. The data 
presented above points to an increased risk for a number of menstrual irregularities in women 
with TSC in addition to the study question of interest (POF). Furthermore these irregularities 
appear to occur with or without a history of seizures or AED use, and outside of correlations to 
TSC severity or genetic testing results. At the very least, further attention to reproductive 
health is necessary for women with TSC, and further research is needed to further identify 
both risk factors and more accurate estimates of the prevalence of such reproductive 
disruptions. 
TSC Diagnosis  
Review of the data characterizing the TSC of these women revealed some noteworthy 
results.  The mean age of diagnosis of TSC was 15 years, ranging from prenatally to 62 years. 
These ages are later than expected, particularly when considering the number of features 
present in infancy or early childhood. However, because of variable expressivity of TSC, it is 
not uncommon for individuals to have a very mild disease and thus subtle presentation. Adults 
are often diagnosed when more severely affected child or family member is ascertained. 
Additionally, 103 of women were age 40 or older at diagnosis, and it is plausible that many 
went undiagnosed prior to increased access and knowledge of genetic services in medicine 
and awareness among practitioners.  We analyzed these two groups for significant differences 
among those diagnosed at a younger age (less than 18 years), and those diagnosed later in 
life (after the age of 18). First, as might be expected, there was a greater severity of TSC in 
those individuals diagnosed at a younger age, indicated by a higher prevalence of intellectual 
disability, learning disabilities, and autism. Furthermore, there were higher percentages of 
angiofibromas, hypopigmented macules, angiomyolipomas, cardiac rhabdomyomas, and 
seizures in the individuals who were diagnosed at a younger age. These results are not 
surprising as many of these clinical features are clues to the diagnosis of TSC. Additionally, of 
the 99 individuals who were diagnosed at a younger age, over 70% of them indicated they did 
not have a family history of TSC (this is consistent with the de novo mutation rate), or did not 
know. A lack of awareness of a dominant genetic condition in one’s family might also impede a 
definitive diagnosis. In contrast, women diagnosed with TSC after the age of 18 had an 
increased frequency of blood tests indicating a menopausal state, a higher pregnancy history, 
higher report of reproductive menopausal symptoms including hot flashes and night sweats, 
higher diagnoses of autoimmune disease, and a higher numbers of reported hysterectomies. 
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Some of these findings would be expected in older respondents, and accordingly, the average 
age of 82 respondents who were diagnosed at age 18 years or older was 51.1 years (±10.6). 
Thus, the findings discussed are more likely to be found in a population of older women. 
Despite these possible confounders, the later age of diagnosis in a sample of mostly 
independent women who belong to a national support group likely underestimates a more 
widespread lack of awareness and diagnosis of affected individuals nationwide, especially 
those with mild disease. 
Mood Disorders 
Another important finding from the data is the high prevalence of mood disorders in 
women affected with TSC. Detailed data is presented in Table 18. The diagnoses of anxiety, 
depression, obsessive compulsive disorder (OCD), and bipolar disorder (BPD), taken together, 
were observed in 93 of women (51.1%). Studies examining psychological distress in TSC 
have found anxiety and depression to be the most common, particularly in women [Pulsifer]. 
Previous studies have found a prevalence of anxiety of up to 56% and depression of up to 
43% in adults with TSC [Lewis; Raznahan]. A large contributing factor to this prevalence of 
psychiatric illness is the individual’s history of seizures. Individuals with epilepsy in the general 
population have higher rates of depression, anxiety, and other mood disorders, and 
particularly those individuals with a higher frequency of seizures [Thompson; Kanner]. This 
background risk makes medication difficult as individuals are often taking additional 
medication to reduce their seizures. In our sample, 57 women (50%) of those with an apparent 
mood disorder reported a history of seizures. About 50% of these women reported a seizure 
frequency of less than once a year, while about 40% reported frequencies ranging from once 
every six months -  once a week. Next, as previously discussed, the rates of depression are 
also higher in women with a diagnosis of POF [Schmidt], and may present prior to the actual 
time of diagnosis. In the general population mood disorders are estimated to affect about 9.5% 
of adult individuals, at an average onset of 30 years [NIMH]. Women are more likely to be 
affected, particularly those of Caucasian ethnicity, and it is thought that 1 in 8 women will 
develop clinical depression in some time during her life [NIMH, 1999]. Therefore, it is likely that 
a woman affected with TSC experiencing menstrual irregularities has an even higher risk to 
develop mood disorders when compared to any three of these considerations alone.  Risk of 
psychological problems warrants further attention by clinical providers for women with TSC, 
and they should be counseled accordingly and/or referred to appropriate specialists to 
optimize their well-being. When we analyzed women reporting a history of mood disorder, we 
found statistically significant differences in comparison to women without illness. Provided in 
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Table 18, these included higher percentages of hot flashes and night sweats, consistent with a 
possible presentation of POF. A higher frequency of reported High blood pressure may be 
related to side effects of medication, or found commonly in the general adult US female 
population, but this same finding was also a significant difference among our sample of seven 
women with possible POF. Regarding mood disorders, we did not observe any differences 
directly related to manifestations specific to TSC. It may be that women who have a baseline 
risk for mood disorders from gender alone, increased through the presence of a genetic 
disorder involving epilepsy, could face a higher risk from problems related to menstrual 
dysfunction or reproductive issues. It would be prudent for healthcare providers to address 
these issues with women while managing their TSC. Forty-four women (24.2%) reported use 
of psychotropic non-seizure medication, and women took an average of 1.5 of these classes of 
medicine A significant portion of women who reported mood disorder are not receiving 
medication (49 women, or 52.7% of those reporting a mood disorder). Secondly, as multiple 
medications are needed and likely contribute to additional side effects which must be 
considered in light of the number of medications these women are prescribed for the 
management of TSC alone. Perhaps these women need additional psychiatric support, and 
would possibly benefit from the use of other services attending to psychiatric illness, including 
psychotherapy. It also suggests that not all psychiatric manifestations arise from TSC alone, 
and women may be unaware of additional, unrecognized menstrual problems contributing to 
their psychiatric health.  
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 Strengths and Limitations 
The present study is strengthened by the use of thorough personal reproductive history, 
and numerous questions aimed at addressing other known causes of POF, and menstrual 
irregularity. The questionnaire was detailed and thorough. The majority of participants filled it 
out sufficiently enough for inclusion in the study.. Furthermore, the data are considered 
reliable, reflecting personal histories of mostly independent women of higher socio-economic 
status involved in their medical care. Our sample size of 182 presents a good representative 
number of women affected with TSC, and allows for the identification of a reproductive 
disorder reported to be present in only 1% of women. The prevalence determined from our 
study may be an underestimate. A larger sample size would allow the research to identify 
whether even more women are affected. 
  Limitations include those common to self-reported questionnaire data. A number of 
women were old enough to make recollection of menstrual history in the 30s more difficult. 
Additionally, the use of oral contraceptives could mask other women who may have had 
unrecognized menstrual dysfunction.  Infertility specialists often diagnose women with POF as 
part of an infertility evaluation. As over 40% of women remained single in our sample, and a 
number stopped having children by their 30s, fewer women may be aware of underlying 
menstrual irregularities. We were also limited in our inability to verify diagnosis of either TSC 
or POF in these women. However, when considering dermatological, renal, cardiac, 
pulmonary manifestations of TSC and the presence of seizures, we observed the presence of 
at least one affected organ system or seizure history in 100% of women. Ninety-three percent 
of women had more than one affected organ system or a seizure history, over two-thirds have 
manifestations in at least three areas, and 9.34% had manifestations in all five. We would thus 
expect these women were indeed affected with TSC. The second issue was addressed by 
applying stringent criteria to evaluate menstrual history for the presence of POF. Menstrual 
trends of regular cycles to irregular cycles were an initial filter, and women with inconsistent or 
contradictory information were further excluded. Additionally, a diagnosis of POF requires 
corresponding values of LH and FSH, which we were not able to obtain. These issues and 
other missing data may contribute to an underestimate of other women with an unrecognized 
progression to menstrual irregularity or POF. Our sample population reflects a bias not 
uncommon in study populations ascertained from national support groups, and may be less 
reflective of TSC, particularly as our analysis of mostly independent women appearing to have 
milder disease was evidenced by the lower percentages of women reporting a history of 
seizures, and fewer indications of cognitive or psychiatric impairment. It is expected that 90% 
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of individuals with TSC will have or have had seizures, and about half are expected to have 
some cognitive impairment or psychiatric disturbance [Prather]. Finally, TSC shows no ethnic 
predilection, but our study was primarily conducted on Caucasian women. Additional risk 
factors that may or may not be present in other ethnic populations were essentially unstudied 
in this research 
Future Directions 
Data from the present study unveils previously unrecognized gender-specific 
manifestations of TSC and highlights a need for future studies assessing the reproductive 
health of women with TSC. More work is needed to elucidate the risk of reproductive 
dysfunction in women with TSC. It will be important to assess longitudinal FSH and LH levels 
in women with TSC from age 30 to 40. Such laboratory studies along with better reproductive 
histories would make the diagnosis of POF more definitive and provide a better prevalence in 
the TSC population. Women receiving radiation therapy in the brain may need to be monitored 
for ovarian function following treatment and recognition of possible effects on the 
hypothalamic-pituitary axis. Lastly, referral to reproductive specialists may be important, 
particularly to bring attention to other disease separate from more familiar manifestations of 
TSC. 
Traditional mechanisms of TSC associated manifestations involve loss of heterozygosity 
and haploinsufficiency [(Castro; Wilson]. It is unknown which, if either, of these are likely 
responsible for the effect on ovarian function observed in the women studied. The original data 
from the mouse models suggested that LOH would be the likely mechanism of POF. Complete 
loss of either Tsc1 or Tsc2 in primordial follicles led to increased activation of mTORC1 and 
the entire population of oocytes [Adkihari 2009, 2010]. The mutant mice were initially fertile 
with normal litter sizes; however litter size progressively decreased until POF and infertility 
occurred. Our data suggests that similar events may occur in the ovaries of women with TSC. 
However, in humans, haploinsufficiency may be a more likely explanation to account for the 
gradual and magnitude of decline necessary to deplete ovarian reserve. The data suggest that 
it may be useful to study women with TSC for signs of premature ovarian failure and other 
reproductive disorders. These data also raise the intriguing possibility that the use of mTORC1 
inhibitors may be a potential treatment for TSC-related menstrual dysfunction. Trials of the 
compound rapamycin, a potent and specific mTORC1 inhibitor, have shown great promise for 
SEGAs, angiomyolipomas, and facial angiofibromas. If up-regulated mTORC1 is 
demonstrated to be a main mechanism of POF in women with TSC, then perhaps rapamycin 
might be a feasible treatment for this newly appreciated manifestation of TSC. Unfortunately 
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the potential teratogenicity of rapamycin might present a problem in its use as a treatment for 
POF.  Rapamycin is registered as Class C and animal studies have indicated embryotoxicity 
and fetotoxicity, which include intrauterine fetal demise, reduced weights, and delayed 
ossification. No adequate studies of pregnant women exist, though successful use of this drug 
during pregnancy has been reported [Jankowska].  
Conclusion 
Our study is the first to assess the presence of menstrual irregularities and reproductive 
dysfunction in a TSC population. We uncovered a significantly elevated prevalence of POF in 
a sample of 182 women belonging to the Tuberous Sclerosis Alliance. The majority of women 
were independent and mildly affected with TSC. They responded to a thorough questionnaire 
and self-reported history of menstrual health and reproductive function, as well as trends in 
menstrual cyclicity. These data were filtered through stringent criteria to determine women 
who progress from regular cycles to irregular cycles, consistent with the development of POF. 
Additional data on reproductive and menstrual health was used to support the possibility of or 
exclude a categorization of possible POF. Nine women were deemed to have possible POF. 
This figure is higher than that previously suggested in the general population, and parallels 
molecular research reported in conditional knock-out mice models of TSC.  The research 
suggested dysregulation of mTORC leading to problems in murine ovarian function, and 
indeed, this may also be implicated in women’s health. When comparing these 9 women with 
possible POF to independent women in the sample population over the age of 30, no 
connections to other variables, overall TSC severity, or a history of seizures / anti-epileptic 
drugs were found. These results suggest that TSC per se is likely predisposing these women 
to POF. 
In addition to specific results of POF in this population, we identified other notable 
findings, also previously unreported. First, we observed that the women in our sample 
experienced a higher rate of miscarriage, and at an earlier age than is expected for the 
general population. In our analysis of menstrual trends, we found that over one-third of women 
had some sort of irregularity, and may be an underestimate as we could not analyze data for 
women using oral contraceptives or those that did not recall their prior menstrual regularity. 
Outside of menstrual health, we also found that the women studied had a later age of 
diagnosis than is typical for TSC. As would be expected, individuals who were diagnosed 
earlier were more likely to have seizures and be dependent. Lastly, the presence of mood 
disorders such as depression, anxiety, OCD, and BPD were elevated in our population, 
signifying a possible additive effect of gender, the genetic disorder TSC, and menstrual 
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irregularities on mental health. Furthermore, not all of these women were receiving 
psychotropic medication. More attention is needed to resolve some of these issues with 
women’s well-being, in addition to increased awareness of other reproductive issues in women 
with TSC. In the absence of clinical data but with stringent menstrual trend criteria, supporting 
reproductive data, and reliable self-reporting, our findings present a reasonable possibility of 
POF or ovarian insufficiency in women with TSC. However, a lack of reporting and a sample 
population with some ascertainment bias calls for further work to elucidate this risk and bring 
attention to other issues in these women. The use of clinical laboratory information will further 
the research suggesting the possible connection with TSC and POF.  
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Appendix A. Survey Questionnaire  
 
Tuberous Sclerosis Complex / Reproductive Health Questionnaire 
  
This questionnaire is designed to learn if Tuberous Sclerosis Complex (TSC) affects a 
woman’s reproductive health.  Specifically, we are interested in a condition known as 
Premature Ovarian Failure (POF), in which the ovaries stop working normally before the age 
of 40. Currently very little is known about how TSC might affect ovarian function, but more 
information will be helpful to people with TSC.  We have designed this questionnaire to learn a 
little about you or your affected family member (demographics), about the severity of your 
TSC, and about your past and current reproductive health. Please keep in mind no personal 
information will be used. We greatly appreciate your help with this research project.  
 
Instructions: 
 
The enclosed envelope includes return postage for one survey. If there is more than 
one female with TSC over the age of 18 in your household we ask that you complete a 
questionnaire for each individual. You may make a copy of this survey and provide your 
own postage to return it. Or you may request another one, either through the TS 
Alliance, by emailing tscstudy@yahoo.com, or by phone to Emily Gabitzsch (713 500 
5760). We will not keep or share any of your personal information.  
 
Please answer the questions (circle the numbers, responses, or write in as requested) about 
you or your affected family member as best as possible and return the questionnaire in the 
enclosed addressed envelope.  
 
If you are unsure about an answer or do not wish to respond, please mark “Don’t Know (D/K)” 
or leave it blank. Should you have any specific questions about the survey, you can send an 
email to tscstudy@yahoo.com for assistance. 
 
These questionnaires are anonymous. Please do not include your name, address or any other 
information that would allow us to identify you.  Please be aware these questions are for 
research purposes only and are not related to the medical supervision by your primary, or 
specialty healthcare providers. We thank you very much for sharing this information. Results of 
this study will be available through the Tuberous Sclerosis Alliance. 
 
Sincerely, 
 
Michael J. Gambello, MD, PhD   Emily Gabitzsch, BS 
Associate Professor of Pediatrics        Genetic Counseling Student 
UT Health             UT Health  
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*****Is the person filling out this questionnaire affected with TSC?***** 
 Yes: please continue to Part 1 
 No: please answer all of the questions with respect to the individual with TSC 
 
Part 1 – Demographics: 
 
Age: ___________    Height __________   Weight _________ 
1) What is your ethnicity?  
 Caucasian, non-Hispanic        
    
 African-American         
   
 Hispanic          
   
 Asian           
   
 Other, please specify ___________________________________   
  
 
2) What is your current marital status? 
 
 Single 
 Married 
 Divorced          
  
 Widowed          
  
 
3) Who do you currently live with? 
  
 Alone           
 With family members         
  
 With a significant other        
  
 With unrelated individuals in an assisted living environment   
  
 Other, please specify ____________________________________  
    
4) What is the highest level of education you’ve completed? 
 
 Under 12th grade         
   
 Completed 12th grade         
  
 Some college          
  
 Associate’s degree         
  
 Bachelor’s degree         
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 Master’s degree or higher        
  
 
5) What is your current employment status? 
  
 Unemployed          
   
 Employed part-time         
  
 Employed full-time         
   
 Student          
   
 Other _________________________________    
 
6) Optional: Which of the following best describes your approximate household yearly 
income? 
 Less than $10,000         
   
 $10,000 – $24,999         
   
 $25,000 – $49,999         
   
 $50,000 – $74,999         
   
 $75,000 – $100,000         
   
 More than $100,000         
   
 Prefer not to answer 
       
Part 2 – General and Reproductive Health:  
7a) Have you ever had a period? (circle one)   
   Yes    No (please skip to question 9)   
 b) If yes, how old were you when you had your first period? ______ years 
8a) Have you ever been pregnant? (circle one)      
            
   Yes    No (please skip to question 9) 
   
 b) How many live births have you had?                              ________ 
  
 c) How many preterm births have you had, if any?                    ________ 
 d) Please indicate your age at each delivery, in years 
 
Pregnancy # My age at delivery, in years 
1  
2  
3  
4  
5  
6  
7  
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e) Have you ever had a miscarriage? (circle one) 
Yes    No    Don’t Know 
 f) If yes, please indicate your age at each miscarriage 
Miscarriage # My age, in years 
1  
2  
3  
4  
5  
6  
 
g) Have you ever had a voluntary termination? (circle one) 
 
Yes    No    Don’t Know 
h) If yes, how many? ________  
9) The chart below is about your menstrual history, since you first got your period. 
Please circle the appropriate response in each column for each range.  
**PLEASE FILL OUT THE CHART FOR EACH AGE RANGE UP TO AND INCLUDING 
YOUR CURRENT AGE.**For example, if you are 22, please only complete rows 1 and 2. 
If you are 36, please complete rows 1 through 5, etc. 
. 
Row 
# 
Age 
range 
(in 
years) 
For the MAJORITY of this age range, 
my periods were : 
For the MAJORITY of this age 
range, I took : 
Regular:       10 
or more periods 
per year 
OR 
Irregular:     9 
or less periods 
per year, or 0 
Oral contraceptive pills or had an 
intrauterine contraceptive device 
(IUD) in place: 
              
1 16-20 Regular   Irregular Yes No 
2 21-25 Regular   Irregular Yes No 
3 26-30 Regular   Irregular Yes No 
4 31-35 Regular   Irregular Yes No 
5 36 Regular   Irregular Yes No 
6 37 Regular   Irregular Yes No 
7 38 Regular   Irregular Yes No 
8 39 Regular   Irregular Yes No 
9 40 Regular   Irregular Yes No 
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10) Please indicate what medications, supplements, and/or vitamins you are currently 
taking. Please specify the name and dose, if known.  
 
Name  Dose How often you take this medicine 
   
   
   
  
 
 
 
 
 
11) Please choose the appropriate response in EACH row to indicate if you have 
experienced any of the following symptoms, within the past year or at any time, and 
indicate how long those symptoms continued, in years.  
  
Symptom Ever Within the past year 
Overall 
duration        (in 
years) 
Hot Flashes Yes No Yes No  
Night Sweats Yes No Yes No  
Excess body hair Yes No Yes No  
Acne Yes No Yes No  
High blood pressure Yes No Yes No  
Milky discharge from the breasts  
 (when not breastfeeding) Yes No Yes No  
Weight gain over 25 pounds,  
not including gain during pregnancy Yes No    
 
12) Have you ever been diagnosed with any of the following? Please circle the 
appropriate response in EACH row. To indicate who diagnosed you, please select from:  
 
General physician, Infertility specialist, endocrinologist, Ob-Gyn, Other, specify: 
 
Name Diagnosed Age (years) Diagnosed By 
Premature Ovarian Failure Yes No Don’t Know   
Polycystic Ovarian Syndrome Yes No Don’t Know   
Amenorrhea 
(no menstrual period) Yes No Don’t Know   
Infertility Yes No Don’t Know   
Anorexia Yes No Don’t Know   
Galactosemia Yes No Don’t Know   
Turner Syndrome Yes No Don’t Know   
Addison Disease Yes No Don’t Know   
Autoimmune Disorder (i.e., 
Lupus) Yes No Don’t Know   
13) Have you ever had a blood test showing the following? Please circle the appropriate 
response for EACH row.              
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Menopausal state  Yes  No    Don’t Know 
Thyroid disease Yes  No Don’t Know 
High testosterone levels Yes  No Don’t Know 
  
14) Have you had any of the following surgeries/procedures? Please circle the 
appropriate response in EACH row.  
 
Procedure Performed Age when performed  (in years) 
Hysterectomy (removal of uterus)
  
Yes  No Don’t Know  
Oophorectomy (removal of ovaries) Yes  No Don’t Know  
Radiation therapy Yes  No Don’t Know  
Chemotherapy Yes  No Don’t Know  
     
 
15 )Please indicate if you have any family members who have also been diagnosed with 
any of the conditions below.  
Please indicate their relationship to you, and the age in years or decade of life (teens, 
30s, 40, etc.) when they were diagnosed.  
 
Diagnosis   Relationship to you Age at diagnosis 
Premature Ovarian 
Failure (menopause 
before age 40) 
No one in 
my family Don’t Know 
1.  
2.  
3.  
Autoimmune 
disorders (i.e. Lupus, 
or under/overactive 
thyroid, rheumatoid 
arthritis) 
No one in 
my family Don’t Know 
1.  
2.  
3.  
Fragile X syndrome No one in 
my family Don’t Know 
1.  
2.  
3.  
 
 
Part 3 – Tuberous Sclerosis Complex (TSC):  
 
16) How old were you when you were diagnosed with TSC (age, in years)? __________ 
 
17a) Do you have any family members who also have TSC? (circle one) 
  
  Yes    No    Don’t Know 
            
b) If yes, please indicate their relationship to you. Please provide their specific 
age in years, or decade of life (teens, 20s, 30s, etc.) when they were diagnosed.  
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Relationship to you Age at diagnosis 
1.  
2.  
3.  
4.   
 
 
 
 
18a) Have you or a family member ever had genetic testing? (circle one)  
 
  Yes    No    Don’t Know 
 
 
 
b) If yes, what were the results? (check one)    
 
 Mutation in TSC1        
 Mutation in TSC2        
 No mutation identified       
   
 Other mutation, please specify: ___________________________  
  
 Don’t Know        
      
19a) Do you have (or have you ever had) a subependymal giant cell astrocytoma 
(SEGA)? (circle one) 
 
  Yes    No (skip to #20)  Don’t Know 
        
 b) If yes, have you received treatment for your SEGA? (circle one)  
            
    Yes    No    Don’t 
Know 
  
c) If yes, what type of treatment did you receive? (check all that apply) 
       
 Surgery          
 Radiation          
 Medication/chemotherapy (including rapamycin)   
 Other, please specify: ____________________________________ 
 
20a) Have you ever had seizures? (circle one)      
            
     Yes    No (skip to #21) 
 Don’t Know    
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 b) If yes, please indicate the age (in years) at which they first started ________
   
c) How often do you have seizures? (please check only one)   
            
   
 At least once a day        
 At least once a week, but not daily       
 At least once a month, but not weekly     
 At least once every six months, but not every month 
 Less than once a year        
 
d) Have you ever had surgery to control your seizures? (circle one)  
     
  Yes    No    Don’t know 
           
 
 
 
e) Please indicate the medications you currently take for your seizures and how 
long (in years) you’ve been taking them. Using a scale from 1 – 3, please indicate 
how effective you believe the medicines are:  
 
                1 (did not work well)      2 (neutral)  3 (worked well)                 ____
  
 
Medication # years Effectiveness (circle one) 
1.  1 2 3 
2.  1 2 3 
3.  1 2 3 
4.   1 2 3 
5.  1 2 3 
 
f) Please indicate the medications you have taken in the past for your seizures 
and how long (in years) you took them for. Using a scale from 1 – 3, please 
indicate how effective you believe these medicines were:  
 
                1 (did not work well)      2 (neutral)  3 (worked well)                 ____
  
 
Medication # years Effectiveness (circle one) 
1.  1 2 3 
2.  1 2 3 
3.  1 2 3 
4.  1 2 3 
5.  1 2 3 
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21) Have you ever been diagnosed with the following? Please circle the appropriate 
response for each row and indicate your age of diagnosis or when symptoms began. 
 
Name Currently Ever Don’t Know Age diagnosed (years) 
Learning disability Yes No Yes No Don’t Know  
ADHD/ADD Yes No Yes No Don’t Know  
Autism Yes No Yes No Don’t Know  
Bipolar Disorder Yes No Yes No Don’t Know  
Depression Yes No Yes No Don’t Know  
Dyslexia Yes No Yes No Don’t Know  
Mental Retardation Yes No Yes No Don’t Know  
Obsessive Compulsive 
Disorder (OCD) Yes No Yes No Don’t Know  
Other, please specify 
___________________ 
Yes No Yes No Don’t Know  
 
 
 
 
 
22) Do you have or have you ever had the following? Please circle the appropriate 
response in each row. 
 
Name Currently Ever Don’t Know 
Facial angiofibromas/adenoma sebaceum/ red 
spots on the face Yes No Yes No Don’t Know 
Ash leaf spots/white birth marks or patches   Yes No Yes No Don’t Know 
Fingernail/toenail tumors   Yes No Yes No Don’t Know 
 
23) Have you ever been diagnosed with the following? Please circle the appropriate 
response for each row and indicate your age at diagnosis. 
 
Name Currently Ever Don’t Know Age diagnosed (years) 
Renal (kidney) cysts Yes No Yes No Don’t Know  
Angiomyolypoma  Yes No Yes No Don’t Know  
Kidney (renal) cancer Yes No Yes No Don’t Know  
                
 
24) Have you ever been diagnosed with the following? Please circle the appropriate 
response for each row and indicate your age of diagnosis or when symptoms began. 
 
Name Currently Ever Don’t Know 
Age of diagnosis or 
symptom onset 
(years) 
Pulmonary (lung) cysts Yes No Yes No Don’t Know  
Lymphangioleiomyomatosis  
(LAM) Yes No Yes No Don’t Know 
 
I experience shortness of 
breath going up one flight of 
stairs 
Yes No Yes No Don’t Know 
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25) Have you ever been diagnosed with the following? Please circle the appropriate 
response for each row and indicate your age when each was noticed. 
 
Name Currently Ever Don’t Know Age noticed (years) 
Rhabdomyomas/ 
Heart tumor Yes No Yes No Don’t Know 
 
Irregular heartbeat Yes No Yes No Don’t Know  
 
26) Are there any other medical problems related to TSC you would like to mention?  
   
   
   
   
   
 
 
 
Conclusion 
 
Congratulations!  You are finished with the Questionnaire.  Please place it in the addressed, 
stamped envelope and mail it back to us.  We thank you again for sharing your time and health 
information.  We hope the results of this study will benefit women with TSC. 
 
Michael J. Gambello, MD, PhD   Emily Gabitzsch, BS 
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Appendix B 
Characteristics of the dependent woman with possible POF 
Briefly, the one dependent woman whose menstrual cycles demonstrated a 
progression from regular to irregular will be described. As mentioned above, she was not 
included in the group of seven women as we chose to compare to independent women only. 
This eighth woman was 46 years old when she had her questionnaire completed by another 
individual. She is African-American and single, lives with family, and is unemployed; she has 
completed some college. Her reported age of menarche was not provided to us in the 
questionnaire. This woman has no reported pregnancies. She did experience normal cyclicity 
between the ages of 16 and 35, but after age 36 irregular cycles were reported; she has never 
used oral contraceptives. Of note, she did have a hysterectomy and oophorectomy at age 37. 
Our participant was also reported to have radiation therapy at age 24, but a specific  
 
We do not have menstrual reporting for ages Her reproductive history is negative for 
blood tests, diagnoses, symptoms, or surgeries, per report. This woman does have a history of 
seizures, with an onset of 6 months. She experiences seizures approximately once per month. 
In the past, this woman used levetiracetam and topiramate for seizure control, each for one 
month. Her current medications include valproic acid, phenobarbital, (taken for 31 years), and 
clonazepam (taken for 16 years). She did receive genetic testing and her results were reported 
as no mutation identified. Interestingly, the only clinical manifestations of TSC reported for this 
woman were angiofibromas and hypopigmented macules. She also has diagnoses of autism 
and mental retardation, both at age 2.  This woman meets the menstrual history criteria set for 
a categorization of possible POF. She does lack additional reproductive data to solidify this 
possibility; however, she does not have contradictory information. It is possible that her current 
use of medication for seizures could contribute to her menstrual irregularity as discussed 
above. As a general comparison to other dependent women between the ages of 30 and 40, 
she appears to differ only in the small number of TSC manifestations, as she does not exhibit 
findings in the cardiac, renal, or pulmonary systems. Our choice to exclude this woman from 
the analysis was based on her differences due to her being dependent, but at a glance, she 
does not appear to exhibit significant differences. 
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